


THE NEW JOURNAL OF UROLOGY



Türkoğlu S, Göya C, Demir M. Zinner Syndrome Versus Herlyn-Werner-Wunderlich syndrome; Rare Congenital Genitourinary Malformations and Literature Review. *New J Urol.* 2024;19(2):95-102.

Evaluation of Time Perception in Individuals with Lifelong Premature Ejaculation

Serkan Aksu, Harun Bal, Hüseyin Tarhan, Hasan Deliktaş, Hayrettin Şahin

Liraglutide Attenuates Gentamicin-Induced Nephrotoxicity in Rats by Reducing Oxidative Stress

Recep Burak Değirmençtepe, Muammer Bozkurt, Osman Can, Mustafa Erkoç, Hazal Öztürk Gürgen, Funda Yıldırım, Fatih Hunç, Fatma Ceyla Eraldemir, Alper Ötünçtemur

Metabolic Risk Factors in Children with Urinary System Stones

Mahmut Çivilibal, Ata Mert Çivilibal, Mesrur Selçuk Silay

Inter-Observer Reliability and Reproducibility of CROES, Guy's and STONE Nephrolithometry Scoring Systems for Predicting Percutaneous Nephrolithotomy Outcomes

Ali Ayrancı, Ufuk Çağlar, Hakan Çakır, Arda Meriç, Ufuk Can Aksu, Faruk Özgör, Ömer Sarılar

The Role of Hematologic Parameters in Predicting Orchiectomy for Testicular Torsion

Cengiz Çanakcı, Erdinç Dinçer, Orkunt Özkaptan, Medet Sevinç, Bilal Eryıldırım

Zinner Syndrome Versus Herlyn-Werner-Wunderlich syndrome; Rare Congenital Genitourinary Malformations and Literature Review

Saim Türkoğlu, Cemil Göya, Murat Demir

THE
NEW JOURNAL
OF UROLOGY

• Volume 19 • Number 2 • June 2024

THE
NEW JOURNAL

OF UROLOGY

New J Urol
eISSN 3023-6940

Volume 19 / Number 2 / June 2024

Grant Holder
Ali İhsan Taşçı

Editor-in-Chief
Ali İhsan Taşçı

Editor
Yavuz Onur Danacıoğlu

Deputy Editor-in-Chief
Mithat Ekşi

Managing Editor
Fatma Taşçı

Biostatistical Editor
Salih Polat

Language Editor
Serda Güzel

Copy Editors
Murat Şahan
Samet Şenel

Digital Media Editor
Mustafa Soytaş

Publishing Service
Pera Publishing Services
🌐 <https://www.perayayincilik.com/>

Publishing Coordinator
Seda Karlıdağ

Contact
Istanbul St. Yenimahalle Mah. Kosk Apt.
N:113/A Bakırköy / Istanbul
☎ 0533 726 72 55
🌐 www.newjournalurology.com

The New Journal of Urology is an international peer-reviewed journal, published triannually (in February, June, October). Publication languages is English. All responsibility for the submitted and published content rests solely with the author(s).
Published content can be cited provided that appropriate reference is given.

Indexed by
TÜBİTAK-ULAKBİM TR-Dizin, DOAJ, EBSCO, Index Copernicus, SCILIT, Google Scholar, Türk Medline Pleksus, Türkiye Atıf Dizini, SOBIAD, OAJI, İdeal Online, EuroPub, J-GATE

OPEN ACCESS



Dear Colleagues,

We are pleased to have published the second issue of The New Journal of Urology for 2024. This issue includes five (5) original articles and one (1) case report. We believe that all the current articles will be read with interest and these articles are expected to contribute to the literature and serve as a reference for future studies.

The New Urology Journal has been indexed in the TÜBİTAK-ULAKBİM TR Index since the first issue of 2011. Our journal is indexed in Google Scholar, Turkish Medline, Turkish Citation Index, SOBIAD, OAJI, İdeal Online Database, EuroPub, J-GATE, and DOAJ databases, EBSCO and InfoBase Index. In addition, the New Journal of Urology is in collaboration with the Orcid and CrossRef DOI systems. The indexing process of our journal in ESCI, Pubmed, and EMBASE continues. The editorial team is very grateful to all the authors and reviewers who have contributed to this issue.

We are aware that this is a painstaking effort, and we cannot thank you enough for it. We request that you submit your articles to The New Journal of Urology, take timely and rigorous action as a referee, and read the articles published in the journal and cite them where appropriate.

Respectfully yours,

Ali İhsan Taşçı
Editor-in-Chief

Yavuz Onur Danacıoğlu
Editor

EDITORIAL BOARD

Editor-in-Chief

Ali Ihsan TASCİ
Department of Urology, Dr.Sadi Konuk
Training and Research Hospital,
Istanbul/TURKEY
E-mail: alihhsantasci@hotmail.com
ORCID ID: 0000-0002-6943-6676

Editor

Yavuz Onur DANACIOĞLU
Department of Urology, Dr.Sadi Konuk
Training and Research Hospital,
Istanbul/TURKEY
E-mail: dr_yonur@hotmail.com
ORCID ID: 0000-0002-3170-062X

Deputy Editor-in-Chief

Mithat EKSI
Department of Urology, Dr.Sadi Konuk
Training and Research Hospital,
Istanbul/TURKEY
E-mail: mithat_eksi@hotmail.com
ORCID ID: 0000-0003-1490-3756

Biostatistical Editor

Salih POLAT
Department of Urology, Amasya
University Sabuncuoglu Serefeddin
Training and Research Hospital,
Amasya/TURKEY
E-mail: salihpolat@gmail.com
ORCID ID: 0000-0002-7580-6872

Language Editor

Serda GUZEL
Department of Translation and
Interpreting, Istanbul Arel University,
Istanbul/TURKEY
E-mail: serdaguzel@arel.edu.tr
ORCID ID: 0000-0001-5212-9891

Copy Editors

Murat SAHAN
Department of Urology, İzmir Bozyaka
Training and Research Hospital, İzmir/
TURKEY
E-mail: dr.msahan@gmail.com
ORCID ID: 0000-0002-0065-4245

Samet SENEL

Department of Urology, Ankara City
Hospital, Ankara/TURKEY
E-mail: samet_senel_uml@hotmail.com
ORCID ID: 0000-0003-2280-4192

Digital Media Editor

Mustafa SOYTAS
Clinical Fellow of Urooncology
Division of Urology and Uro-oncology,
McGill University
Montreal, QC, Canada
E-mail: drmustafasoytas@gmail.com
ORCID ID: 0000-0002-3474-3510

BOARD MEMBERS

Abdullah Erdem CANDA
Department of Urology, Faculty of
Medicine, Koc University, Istanbul/
TURKEY
E-mail: erdemcanda@yahoo.com
ORCID ID: 0000-0002-5196-653X

Ahmad MOTAWI
Department of Andrology Faculty of
Medicine, Cairo University/Egypt
E-Mail: a7madmotaw3@gmail.com
ORCID ID: 0000-0003-0962-0604

Ahmet Rahmi ONUR
Department of Urology, Faculty of
Medicine, Firat University, Elazığ/
TURKEY
E-mail: rahmionur@yahoo.com
ORCID ID: 0000-0001-6235-0389

Ahmet Yaser MUSLUMANOĞLU
Department of Urology, Bağcılar
Training and Research Hospital,
Istanbul/TURKEY
E-mail: y musulmanoglu56@hotmail.com
ORCID ID: 0000-0002-8691-0886

Ali Serdar GOZEN
Department of Urology, SLK Klinikum
Heilbronn, Am Gesundbrunnen 20,
Heilbronn, GERMANY
E-mail: asgozen@yahoo.com
ORCID ID: 0000-0002-2205-5876

Asif YILDIRIM
Department of Urology, Goztepe
Medeniyet University, Istanbul/TURKEY
E-mail: asifyildirim@yahoo.com
ORCID ID: 0000-0002-3386-971X

Archil CHKHOTUA
L. Managadze National Center of
Urology
E-mail: achkhotua@gmail.com
ORCID ID: 0000-0002-0384-8619

Arunas ZELVYS
European Association of Urology,
European Board of Urology, Vilnius
University Hospital Santariskiu Klinikos
Vilnius, Lithuania
E-mail: arunas.zelvys@santa.lt
ORCID ID: 0000 0002 9778 9372

Ates KADIOĞLU
Department of Urology, Faculty of
Medicine, Istanbul University, Istanbul/
TURKEY
E-mail: kadiogluates@ttnet.net.tr
ORCID ID: 0000-0002-5767-4837

Badrinath KONETY
Allina Health Cancer Institute -
Minneapolis
E-mail: badrinath.konety@allina.com
ORCID ID: 0000-0002-1088-3981

Fatih YANARAL
Department of Urology, Memorial Şişli
Hospital, Istanbul/TURKEY
E-mail: fatihyanaral@gmail.com
ORCID ID: 0000-0002-7395-541X

Hashim HASHİM
Bristol Urological Institute, Southmead
Hospital, Bristol, Somerset, UK.
E-mail: h.hashim@gmail.com
ORCID ID: 0000-0003-2467-407X

Ihsan KARAMAN
Department of Urology, Medistate
Kavacik Hospital, Istanbul/TURKEY
E-mail: mikaraman@hotmail.com
ORCID ID: 0000-0003-3275-3202

Imad ZİOUZİOU
Department of Urology, College of
Medicine and Pharmacy, Ibn Zohr
University, Agadir, Morocco
E-mail: imadziouziou@hotmail.com
ORCID ID: 0000-0002-9844-6080

Jean De La ROSETTA
Department of Urology, Istanbul
Medipol University, Istanbul/TURKEY
E-mail: jdelarosette@medipol.edu.tr
ORCID ID: 0000-0002-6308-1763

Jeremy Y. C. TEOH
Prince of Wales Hospital, Shatin, Hong
Kong.
E-mail: jeremyteoh@surgery.cuhk.edu.hk
ORCID ID: 0000-0002-9361-2342

Joyce BAARD
Amsterdam UMC, University of
Amsterdam, Amsterdam, the
Netherlands.
E-mail: j.baard@amsterdamumc.nl
ORCID ID: 0000-0002-5509-0213

Kemal SARICA
Department of Urology, Kafkas
University, Kars/TURKEY
E-mail: kemalsarica@superonline.com
ORCID ID: 0000-0001-7277-3764

M. Derya BALBAY
Department of Urology, Şişli Memorial
Hospital, Istanbul/TURKEY
E-mail: derya.balbay@memorial.com.tr
ORCID ID: 0000-0003-0060-5491

Mahmut GUMUS
Department of Medical Oncology,
Faculty of Medicine, Medeniyet
University, Istanbul/TURKEY
E-mail: mahmut.gumus@medeniyet.edu.tr
ORCID ID: 0000-0003-3550-9993

Mesrur Selcuk SILAY
Department of Urology, Bahçelievler
Memorial Hospital, Istanbul/TURKEY
E-mail: selcuksilay@gmail.com
ORCID ID: 0000-0001-5091-9654

Murat BOZLU
Department of Urology, Faculty of
Medicine, Mersin University, Mersin/
TURKEY
E-mail: muratbozlu@yahoo.com
ORCID ID: 0000-0002-8624-0149

Mohammed SAID SULAIMAN
Department of Surgery, St. Paul's
Hospital Millennium Medical College,
ETHIOPIA
E-mail: bensulaimani@gmail.com

Oner SANLI
Department of Urology, Faculty of
Medicine, Istanbul University, Istanbul/
TURKEY
E-mail: onersanli@hotmail.com
ORCID ID: 0000-0001-5801-6898

Osama Kamal ZAKÍ SHAEER
Faculty of Medicine, Cairo University,
Egypt
Email: dr.osama@alrijal.com
ORCID ID: 0000-0002-3811-9969

Paolo GONTERO
Urology Unit, Department of Surgical
Sciences, University of Turin, Italy
E-mail: paolo.gontero@unito.it
ORCID ID: 0000-0002-9714-6596

Pilar LAGUNA

Department of Urology, Istanbul
Medipol University, Istanbul/TURKEY
E-mail: plaguna@medipol.edu.tr
ORCID ID: 0000-0003-0906-4417

Raed AZHAR
Urology Department of King Abdulaziz
University Saudi Arabia Kingdom
E-mail: raedazhar@gmail.com
ORCID ID: 0000-0001-5233-1352

Rajveer PUROHIT
Department of Urology, Mount Sinai
Hospital, New York/USA
E-mail: rajveer.purohit@mountsinai.org
ORCID ID: 0000-0002-5912-8354

Ramazan Gökhan ATİŞ
Department of Urology, Memorial Şişli
Hospital, Istanbul/TURKEY
E-mail: gokhanatis@hotmail.com
ORCID ID: 0000-0002-9065-6104

Saad ALDOUSARİ
Department of Surgery of Kuwait
University KUWAIT
E-mail: saad.aldousari@gmail.com
ORCID ID: 0000-0003-1670-9287

Selami ALBAYRAK
Department of Urology, Faculty of
Medicine, Medipol University, Istanbul/
TURKEY
E-mail: salbayrak@medipol.edu.tr
ORCID ID: 0000-0002-4245-7506

Shahid KHAN
Department of Urology, East Surrey
Hospital, London/United Kingdom
E-mail: shahidkhan1@nhs.net
ORCID ID: 0009-0002-3072-1514

Sudhir KUMAR RAWAL
Oncology Services
Rajiv Gandhi Cancer Institute,
E-mail: sunil.kumar@amo.bbott.com
ORCID ID: 0000-0002-3331-2372

Simon TANGUAY
FRCS Professor and Chair Division of
Urology Mostafa Elhilali/David Azrieli
Chair in Urologic Sciences McGill
University
E-mail: simon.tanguay@mcgill.ca
ORCID ID: 0000-0001-6947-304X

Turhan ÇAŞKURLU
Department of Urology, Memorial
Ataşehir Hospital Istanbul/TURKEY
E-mail: tcaskurlu@hotmail.com
ORCID ID: 0000-0002-4471-2670

Volkan TUGCU
Department of Urology, Liv Hospital,
Istanbul/TURKEY
E-mail: volantugcu@yahoo.com
ORCID ID: 0000-0002-4136-7584

Widi Atmoko
Department of Urology, Cipto
Mangunkusumo General Hospital,
Universitas Indonesia
E-mail: dr.widiatmoko@yahoo.com
ORCID ID: 0000-0002-7793-7083

Yodgorov Ibrokhim FAHRRIDDİNOVİCH
Bukhara State Medical University
Bukhara, Uzbekistan
E-mail: ibroxim_yodgorov@mail.ru
ORCID ID: 0000-0001-9563-0686

CONTENTS

Original Research

- Evaluation of Time Perception in Individuals with Lifelong Premature Ejaculation** 61-67
Serkan Aksu, Harun Bal, Hüseyin Tarhan, Hasan Deliktaş, Hayrettin Şahin
- Liraglutide Attenuates Gentamicin-Induced Nephrotoxicity in Rats by Reducing Oxidative Stress** 68-77
Recep Burak Değirmençtepe, Muammer Bozkurt, Osman Can, Mustafa Erkoç, Hazal Öztürk Gürgen, Funda Yıldırım, Fatih Hunç, Fatma Ceyla Eraldemir, Alper Ötünçtemur
- Metabolic Risk Factors in Children with Urinary System Stones** 78-84
Mahmut Çivilibal, Ata Mert Çivilibal, Mesrur Selçuk Silay
- Inter-Observer Reliability and Reproducibility of CROES, Guy's and STONE Nephrolithometry Scoring Systems for Predicting Percutaneous Nephrolithotomy Outcomes** 85-89
Ali Ayrancı, Ufuk Çağlar, Hakan Çakır, Arda Meriç, Ufuk Can Aksu, Faruk Özgör, Ömer Sarılar
- The Role of Heamatologic Parameters in Predicting Orchiectomy for Testicular Torsion** 90-94
Cengiz Çanakçı, Erdinç Dinçer, Orkunt Özkaptan, Medet Sevinç, Bilal Eryıldırım

Case Report

- Zinner Syndrome Versus Herlyn-Werner-Wunderlich syndrome; Rare Congenital Genitourinary Malformations and Literature Review** 95-102
Saim Türkoğlu, Cemil Göya, Murat Demir

Evaluation of Time Perception in Individuals with Lifelong Premature Ejaculation

Serkan Aksu¹, Harun Bal², Hüseyin Tarhan², Hasan Deliktaş², Hayrettin Şahin²

¹Department of Physiology, Faculty of Medicine, Muğla Sıtkı Koçman University, Muğla, Türkiye

²Department of Urology, Faculty of Medicine, Muğla Sıtkı Koçman University, Muğla, Türkiye

Submitted: 2024-01-08

Accepted: 2024-04-30

Correspondence

Serkan Aksu, MD

Department of Physiology,
Muğla Sıtkı Koçman University,
Kötekli, 48000, Muğla, Türkiye
E-mail: serkanaksu@mu.edu.tr

ORCID

S.A. [0000-0001-7715-0320](https://orcid.org/0000-0001-7715-0320)
H.B. [0000-0003-0878-8253](https://orcid.org/0000-0003-0878-8253)
H.T. [0000-0003-1398-1592](https://orcid.org/0000-0003-1398-1592)
H.D. [0000-0002-0973-2318](https://orcid.org/0000-0002-0973-2318)
H.Ş. [0000-0001-8921-2840](https://orcid.org/0000-0001-8921-2840)

Abstract

Objective: Premature Ejaculation (PE) is a common sexual disorder that considerably affects sexual satisfaction, subjective well-being, and quality of life. A clear picture of the pathophysiology of PE has still not been determined. Current research has revealed the involvement of the central nervous system. Alterations in frontal cerebral structures and a discrepancy between the reported and objectively measured intravaginal ejaculatory latency times both point to a possible alteration of time perception. The present study aimed to assess the time perception between individuals with lifelong PE and healthy individuals.

Material and Methods: 24 individuals with lifelong PE and 24 healthy volunteers were recruited. Participants were administered both clinical measures and a time perception test battery including time interval estimation tests and time interval production tests for 4,7,32 and 58-second time intervals.

Results: Lower predictions for 4-second time intervals were found in individuals with lifelong PE than in healthy controls. No differences were found for 7,32 and 58-second time intervals. The Premature Ejaculation Diagnostic Tool scores correlated negatively with the 4-second and 32-second time interval predictions.

Conclusion: The present results indicate a time perception deficit for short intervals in individuals with lifelong PE for the first time. This might be due to a working memory/executive function deficit or disruption of frontal functions on account of impulsivity. A specific deficit in time perception deficit might also occur. Further studies assessing other frontal functions concomitantly are required to draw firm conclusions.

Keywords: Cognitive functions, premature ejaculation, sexual disorders, time perception

INTRODUCTION

Premature Ejaculation (PE) is one of the most common sexual disorders in men that has been characterized by a

loss of ejaculatory control and premature ejaculation before expected sexual satisfaction (1). The prevalence of PE has been estimated to be about 20-30% in Türkiye (2). PE results

in a considerable loss of sexual satisfaction and thereby self-esteem, subjective well-being, and quality of life (1). Since its first definition in 1887, substantial improvement regarding its understanding and more satisfactory treatment outcomes have been reported recently (1,3). While various typologies have been defined, lifelong PE has the best-documented intrinsic pathophysiology. Nevertheless, the exact course and the clear picture of the pathophysiology have not been sketched out thus far (3). A plethora of pathophysiological mechanisms including penile hypersensitivity, 5-HT receptor dysfunction, and anxiety have been identified while numerous others like obesity, sedentary lifestyle, diabetes, and traumatic sexual or emotional experiences have also been depicted to have a possible role (4,5). However, novel insights regarding the contribution of the central nervous system have been gained in the last decade. In animals, various central regions like the medial preoptic area, paraventricular nucleus, periaqueductal grey matter, and lateral paragigantocellular nucleus have been associated with ejaculation (6,7). In these regions, multiple neurotransmitters, especially serotonin, are involved in the processes of ejaculation. In humans, the involvement of the central nervous system in PE is also considered in light of the recent findings. During ejaculation, cranial activity has been indicated to decrease in the medial prefrontal cortex and inferior frontal cortex (8,9). Individuals with PE have also been shown to have functional connectivity alterations in the bilateral medial orbitofrontal cortices, right inferior frontal gyrus, and other cranial brain regions (10–12).

Time perception is a broad term for distinct relevant skills including the ability to measure the time passed between two events, the ability to discriminate the difference between time intervals, etc. which are involved in maintaining numerous daily activities (13). Bearing the wide daily usage in mind, it is not surprising that deficits in some or all aspects of time perception have been revealed in a wide spectrum of neuropsychiatric disorders (14). However, no studies have previously assessed time perception in individuals with lifelong PE. Two main arguments may point to a possible alteration of time perception in individuals with lifelong PE. First, a significant discrepancy between the reported and actual intravaginal ejaculatory latency times has been observed in some of the studies (15,16), but not all of them (17,18). Second, some disruptions have been observed in frontal structures (10,11) which are essentially involved in time perception (19).

The present study aimed to assess the differences in time perception between individuals with PE and healthy individuals. We postulated that specific or generalized alterations in time perception might occur in individuals with PE.

MATERIAL AND METHODS

Design

The present cross-sectional study was conducted in the Department of Urology and the Department of Physiology of the Faculty of Medicine. The study was approved by the local ethical committee (dated 25th December 2022, decision number 91). All participants provided written informed consent. The study procedures complied with the Declaration of Helsinki. Experienced urologists medically examined all participants. No compensation was provided for the participants. The routine medical treatment of the individuals with PE was initiated after completing the study procedures. General mental health status was evaluated with the Patient Health Questionnaire-9 (PHQ-9) (20). The severity of PE was determined with the Premature Ejaculation Diagnostic Tool (PEDT) (21). The International Index of Erectile Function- Erectile Function subscale (IIEF-EF) was utilized to exclude erectile dysfunction (22). Time perception was evaluated with the Time Interval Estimation Tests (TIET) and the Time Interval Production Tests (TIPT).

Participants

Twenty-four treatment-naïve individuals with lifelong PE and twenty-four volunteering healthy control subjects were recruited from the urology outpatient clinic. Healthy volunteers were recruited from the hospital attendants. Lifelong PE diagnosis was performed by the International Society of Sexual Medicine-2014 criteria (23). Exclusion criteria were being aged below 18 or above 60, the lack of a heterosexual monogamic partner, less than four sexual intercourses in the last month as at least four sexual intercourses have been suggested to calculate Intravaginal Ejaculatory Latency Time, serious neurologic, psychiatric, or other medical illness, had a history of major pelvic/penile surgery, had retrograde/painful ejaculation or anejaculation, had a sexual partner with sexual dysfunction, or a serious medical illness (24). Participants with a Body Mass Index above 40 and with a PHQ-9 score of above 10 were also excluded. Participants in the lifelong PE group were treatment-naïve, had a mean Intravaginal Ejaculatory Latency Time of less than one minute in the last month, a PEDT score of more than 11, and an IIEF-EF score of more

than 21 to exclude erectile dysfunction. Participants in the healthy volunteer group had a mean Intravaginal Ejaculatory Latency Time of more than one minute in the last month, a PEDT score of less than 11, and an IIEF-EF score of more than 21 to exclude erectile dysfunction.

Instruments

Premature Ejaculation Diagnostic Tool (PEDT): PEDT is a Likert-type self-report diagnostic tool that consists of five practical items to overall determine the presence and degree of PE in males (21). The approximate application duration is 2 minutes. Total scores above 11 correspond to definite PE while total scores of 10 and 11 correspond to probable PE.

International Index of Erectile Function- Erectile Function subscale (IIEF-EF): The International Index of Erectile Function is a comprehensive 6-point Likert-type scale that involves five main sections as follows: Erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. The IIEF-EF is the subscale that chiefly assesses erectile function status (22). The total score of IIEF-EF was calculated with the sum of the first five items and the fifteenth item. Studies indicated its similar validity to the laboratory tests of EF (25). An IIEF-EF score above 21 is probably adequate to exclude EF.

Patient Health Questionnaire-9 (PHQ-9): PHQ-9 is a common diagnostic screening tool to assess general mental status and to screen major depressive disorder. It is a nine-item self-report Likert-type scale that was mainly based on the Diagnostic and Statistical Manual of Mental Disorders-IV criteria. Turkish reliability and validity of the scale were performed in the general population (20). In PHQ-9; total scores between 0-4 correspond to minimal/no depression, total scores between 5-9 correspond to mild depression, total scores between 10-14 correspond to moderate depression, and total scores between 15-21 correspond to severe depression. Individuals with total scores above 10 have 7-13.6 times higher risk of having clinical major depressive disorder (26).

Time Interval Estimation Tests (TIET): In Time Interval Estimation Tests, participants were asked to estimate the duration between two beep sounds that corresponded to “start” and “stop” commands and then tell the duration of the sound verbally. Participants were previously informed that they would be asked to estimate the duration of the time interval. However, counting verbally or using rhythmic body movements was not allowed. Four distinct time intervals

(4,7,32 and 58 seconds) were each performed thrice (27,28). Therefore, a total of twelve distinct time intervals were estimated. Interval trials were performed in a randomized order. The averages for each four distinct time intervals were calculated. Then, the average of the reported duration for each interval was divided by the exact duration of the time intervals to calculate the Ratios for each interval.

Time Interval Production Tests (TIPT): In Time Interval Production Tests, participants were asked to produce a previously determined time interval. To this end, participants were asked to give the “stop” command verbally when the previously determined time interval had passed after the “start” command. However, counting verbally or using rhythmic body movements was not allowed. Four distinct time intervals (4,7,32 and 58 seconds) were each performed thrice (27,28). Therefore, a total of twelve distinct time intervals were estimated. Interval trials were performed in a randomized order. The averages for each four distinct time intervals were calculated. Then, the average of the reported duration for each interval was divided by the exact duration of the time intervals to calculate the Ratios for each interval.

Statistical Analyses

Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) 25.0 (IBM Corporation, Armonk, NY, USA). Shapiro-Wilk tests were conducted to determine the normality status. All variables except the Ratio of TIPT 4 Seconds were non-normally distributed. Independent Samples T-tests were conducted to compare the normally distributed variables between the lifelong PE and healthy control groups. Mann-Whitney *U* tests were conducted to compare the non-normally distributed variables between the lifelong PE and healthy control groups. A *p*-value below 0.05 was considered significant.

RESULTS

The comparison of the demographic and clinical properties between lifelong PE and healthy control groups is depicted in Table 1. The mean age of the study sample was 32.0 and a significant age difference was found between lifelong PE and healthy control groups ($Z = -4.077$; $p < 0.001$). There were also significant differences in the number of educated years ($Z = -2.661$; $p = 0.008$) and the PEDT scores ($Z = -5.957$; $p < 0.001$), but IIEF-EF scores and the PHQ-9 total scores were similar.

The comparison of the time perception test results is depicted

in Table 2. TIET 4 Seconds Ratios were lower in the lifelong PE group than the healthy control group ($t = 2.268$; $p = 0.029$) (Figure 1). There were no significant differences in the TIET Ratios for 7,32 and 52 Seconds.

The PEDT score correlated with the TIET Ratios for 4 Seconds ($r = -0.287$; $p = 0.048$) and 32 Seconds ($r = -0.303$; $p = 0.036$). There were also correlation trends towards significance between the PEDT score and TIET Ratios for 7 Seconds ($r = -0.273$; $p = 0.060$) and 58 Seconds ($r = -0.284$; $p = 0.051$).




Figure 1. Differences in 4 second (short) time interval between individuals with premature ejaculation and healthy controls. Bars represent standard error.

Table 1. Comparison of Demographic and Clinical Variables Between Individuals with Premature Ejaculation and Healthy Controls

	Variables			
	PE (n=24)	Healthy (n=24)	Z	P-values
Demographic/Clinical Measure				
Age	24.00 (12.50)	36.50 (13.25)	-4.077	<0.001
Education (years)	13.50 (4.00)	16.00 (2.00)	-2.661	0.008
PEDT	17.00 (7.25)	7.00 (6.75)	-5.957	<0.001
IIEF-EF	25.50 (8.00)	24.00 (4.00)	-0.907	0.365
PHQ-9	5.50 (4.50)	6.00 (7.75)	-0.062	0.950

PE: Premature Ejaculation; PEDT: Premature Ejaculation Diagnostic Tool; IIEF-EF: International Index of Erectile Function-Erectile Function; PHQ-9: Patient Health Questionnaire-9. Medians (interquartile ranges) and Z values are shown. Significant p-values are bold.

Table 2. Time Perception Parameters in Individuals with Premature Ejaculation and Healthy Controls

Measures	PE (n=24)	Healthy (n=24)	Total (n=48)	Z/t	p-values
TIET 4 seconds Ratio	0.885 (0.206)	1.000 (0.230)	0.942 (0.181)	2.268	0.029
TIET 7 seconds Ratio	0.900 (0.150)	0.925 (0.130)	0.900 (0.110)	-1.484	0.138
TIET 32 seconds Ratio	0.860 (0.250)	0.900 (0.100)	0.880 (0.120)	-1.566	0.117
TIET 58 seconds Ratio	0.905 (0.160)	0.930 (0.130)	0.910 (0.170)	-1.710	0.087
TIPT 4 seconds Ratio	1.080 (0.120)	1.000 (0.080)	1.040 (0.080)	-1.098	0.272
TIPT 7 seconds Ratio	1.110 (0.410)	1.040 (0.120)	-1.070 (0.250)	-1.061	0.289
TIPT 32 seconds Ratio	1.135 (0.300)	1.075 (0.200)	1.110 (0.290)	-0.827	0.408
TIPT 58 seconds Ratio	1.270 (0.520)	1.150 (0.260)	1.160 (0.430)	-1.469	0.142

PE: Premature Ejaculation; TIET: Time Interval Estimation Test. Mean (standard deviation) and t value for TIET 4 seconds ratio are shown. Medians (interquartile ranges) and Z values for other outcome variables are shown. Significant p-values are bold.

DISCUSSION

The present study intended to assess time perception differences between individuals with lifelong PE and healthy individuals for the first time. Partially consistent with the hypotheses, lower accuracy of the 4-second time estimation was found in individuals with lifelong PE than in healthy controls. Moreover, disease severity as assessed by the PEDT score correlated negatively with the accuracy of the 4-second time estimation. On the other hand, no differences were observed in other time intervals.

The crucial finding of the present study was the alteration of 4-second time interval predictions. Since individuals with PE had lower age than healthy controls, this alteration was not attributable to high age. A variety of reasons might explain this finding. First, this might be due to a slight deficit in working memory/executive functions as there is a significant relationship between time perception and frontal functions (29), and frontal alterations to some extent have been observed in individuals with PE (10,11). Time perception is a multifaceted cognitive function that involves the contribution of numerous cognitive and perceptual processes. Among them, attention and working memory come to the fore which are chiefly maintained by the frontal structures of the brain (29). Auditory and visual inputs are compared with the speed of the internal time clock and integrated with the internal time clock by the prefrontal cortex. This process considerably requires a proper attention/working memory system. However, we did not assess working memory/executive functions and no studies have directly identified a working memory/executive function deficit in individuals with lifelong PE thus far. Nevertheless, previously identified alterations of the frontal structures in individuals with PE might point to a possible attention/working memory deficit (10,11).

Another possible explanation for the lower ratios of the TIET 4 Second test might be impulsivity which might also be associated with the frontal alterations or working memory/executive function deficits. The relationship between short-time-interval estimation and impulsivity supports this notion (30). Even though the neural bases of this assumption have not been exactly identified yet, a theoretical neural model has been suggested that integrates the neural circuits of time perception and impulsivity through the common structures and pathways (30).

Finally, the alteration of time perception in individuals with PE might be also a specific cognitive deficit. Nevertheless, time perception is a complex phenomenon with multiple sub-aspects (13). Thus, further studies are required to draw firm conclusions. It should also be mentioned that we could not determine the order of emergence or the causal link between the PE and the alteration of short-interval time perception since the present study was a cross-sectional study.

A few limitations of the present study should be mentioned. The relatively small sample size, lack of a general cognitive status assessment, and lack of an age-matched control group are the outstanding limitations of the present study.

CONCLUSIONS

To conclude, the present study indicates a significant difference in time perception of a short time interval between lifelong PE and healthy control groups that may point to a specific time deficit or a possible deficit in working memory. However, the present results were not able to confirm these assumptions, and further studies with larger samples are required to draw firm conclusions.

Acknowledgments: The authors would like to thank all the participants who have kindly taken part in this study.

Disclosure statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethics Committee: Muğla Sıtkı Koçman University / Faculty of Medicine (25.12.2022 Decision No: 91).

Author Contributions:

Serkan Aksu: Concept and design, data collection, data analysis and evaluation, writing of the manuscript draft, review of the manuscript draft, statistical analysis, and final approval. Harun Bal, Hüseyin Tarhan, Hasan Deliktaş, Hayrettin Şahin: Concept and design, data collection, data analysis, and evaluation, review of the manuscript draft, statistical analysis, final approval.

REFERENCES

1. Ciocanel O, Power K, Eriksen A. Interventions to Treat Erectile Dysfunction and Premature Ejaculation: An Overview of Systematic Reviews. *Sex Med.* 2019 Sep 1;7(3):251-69. <https://doi.org/10.1016/J.ESXM.2019.06.001>
2. Serefoglu EC, Yaman O, Cayan S, Asci R, Orhan I, Usta MF, et al. Prevalence of the Complaint of Ejaculating Prematurely and the Four Premature Ejaculation Syndromes: Results from the Turkish Society of Andrology Sexual Health Survey. *J Sex Med.* 2011 Feb 1;8(2):540-8. <https://doi.org/10.1111/J.1743-6109.2010.02095.X>
3. Waldinger MD. History of premature ejaculation. *Premature Ejaculation: From Etiology to Diagnosis and Treatment.* Springer-Verlag Italia s.r.l.; 2013. 5-24 p. https://doi.org/10.1007/978-88-470-2646-9_2
4. McMahon CG, Jannini EA, Serefoglu EC, Hellstrom WJG. The pathophysiology of acquired premature ejaculation. *Transl Androl Urol.* 2016 Aug 1;5(4):434-49. <https://doi.org/10.21037/TAU.2016.07.06>
5. El-Hamd MA, Saleh R, Majzoub A. Premature ejaculation: an update on definition and pathophysiology. *Asian J Androl.* 2019 Sep 1;21(5):425. https://doi.org/10.4103/AJA.AJA_122_18
6. Pereira-Lourenço M, Brito DV e, Pereira BJ. Premature Ejaculation: From Physiology to Treatment. *J Family Reprod Health.* 2019 Dec 25;13(3):120. <https://doi.org/10.18502/jfrh.v13i3.2125>
7. Soni KK, Jeong HS, Jang S. Neurons for Ejaculation and Factors Affecting Ejaculation. *Biology (Basel).* 2022 May 1;11(5):686. <https://doi.org/10.3390/BIOLOGY11050686>
8. Holstege G, Georgiadis JR, Paans AMJ, Meiners LC, Van der Graaf FHCE, Reinders AATS. Brain Activation during Human Male Ejaculation. *J Neurosci.* 2003 Oct 10;23(27):9185-9193. <https://doi.org/10.1523/JNEUROSCI.23-27-09185.2003>
9. Georgiadis JR, Kringelbach ML. The human sexual response cycle: brain imaging evidence linking sex to other pleasures. *Prog Neurobiol.* 2012 Jul;98(1):49-81. <https://doi.org/10.1016/J.PNEUROBIO.2012.05.004>
10. Chen J, Huang X, Lu C, Liu T, Dai Y, Yao Z, et al. Graph analysis of DTI-based connectome: decreased local efficiency of subcortical regions in PE patients with high sympathetic activity. *Andrology.* 2020 Mar 1;8(2):400-6. <https://doi.org/10.1111/andr.12701>
11. Gao M, Yang X, Liu L, Fei N, Xi Y, Guo F, et al. Abnormal White Matter Microstructure in Lifelong Premature Ejaculation Patients Identified by Tract-Based Spatial Statistical Analysis. *J Sex Med.* 2018 Sep 1;15(9):1272-9. <https://doi.org/10.1016/J.JSXM.2018.07.012>
12. Lu J, Yuan L, Jin J, Yang S, Zhang W, Li M, et al. Brain Cortical Complexity and Subcortical Morphometrics in Lifelong Premature Ejaculation. *Front Hum Neurosci.* 2020 Jul 22;14:543711. <https://doi.org/10.3389/FNHUM.2020.00283>
13. Block RA, Grondin S. Timing and time perception: A selective review and commentary on recent reviews. *Front Psychol.* 2014 Jul 29;5:99030. <https://doi.org/10.3389/FPSYG.2014.00648>
14. Hinault T, D'Argembeau A, Bowler DM, La Corte V, Desautay P, Provasi J, et al. Time processing in neurological and psychiatric conditions. *Neurosci Biobehav Rev.* 2023 Nov 1;154:105430. <https://doi.org/10.1016/J.NEUBIOREV.2023.105430>
15. Lee WK, Cho ST, Lee YS, Lee YG, Oh CY, Yoo C, et al. Can estimated intravaginal ejaculatory latency time be used interchangeably with stopwatch-measured intravaginal ejaculatory latency time for the diagnosis of lifelong premature ejaculation? *Urology.* 2015 Feb 1;85(2):375-80. <https://doi.org/10.1016/J.UROLOGY.2014.09.036>
16. Albakr A, Arafa M, Elbardisi H, ElSaid S, Majzoub A. Premature ejaculation: An investigative study into assumptions, facts and perceptions of patients from the Middle East (PEAP STUDY). *Arab J Urol.* 2021;19(3):303-9. <https://doi.org/10.1080/2090598X.2021.1948159>
17. Waldinger MD, McIntosh J, Schweitzer DH. A five-nation survey to assess the distribution of the intravaginal ejaculatory latency time among the general male population. *J Sex Med.* 2009;6(10):2888-95. <https://doi.org/10.1111/J.1743-6109.2009.01392.X>
18. Rosen RC, McMahon CG, Niederberger C, Broderick GA, Jamieson C, Gagnon DD. Correlates to the clinical diagnosis of premature ejaculation: results from a large observational study of men and their partners. *J Urol.* 2007 Mar;177(3):1059-64. <https://doi.org/10.1016/J.JURO.2006.10.044>

19. Nani A, Manuello J, Liloia D, Duca S, Costa T, Cauda F. The Neural Correlates of Time: A Meta-analysis of Neuroimaging Studies. *J Cogn Neurosci*. 2019 Dec 1;31(12):1796-826. <https://doi.org/10.1162/JOCN.A.01459>
20. Kocalevent RD, Hinz A, Brähler E. Standardization of the depression screener patient health questionnaire (PHQ-9) in the general population. *Gen Hosp Psychiatry*. 2013 Sep;35(5):551-5. <https://doi.org/10.1016/J.GENHOSPPSYCH.2013.04.006>
21. Serefoglu EC, Cimen HI, Ozdemir AT, Symonds T, Berktaş M, Balbay MD. Turkish validation of the premature ejaculation diagnostic tool and its association with intravaginal ejaculatory latency time. *Int J Impot Res*. 2009 Mar 9;21(2):139-44. <https://doi.org/10.1038/IJIR.2008.58>
22. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology*. 1997 Jun;49(6):822-30. [https://doi.org/10.1016/S0090-4295\(97\)00238-0](https://doi.org/10.1016/S0090-4295(97)00238-0)
23. Althof SE, McMahon CG, Waldinger MD, Serefoglu EC, Shindel AW, Adaikan PG, et al. An Update of the International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE). *Sex Med*. 2014 Jun 1;2(2):60-90. <https://doi.org/10.1002/SM2.28>
24. Zohdy W. Clinical parameters that predict successful outcome in men with premature ejaculation and inflammatory prostatitis. *J Sex Med*. 2009;6(11):3139-46. <https://doi.org/10.1111/J.1743-6109.2009.01487.X>
25. Daker-White G. Reliable and valid self-report outcome measures in sexual (dys)function: a systematic review. *Arch Sex Behav*. 2002 Apr;31(2):197-209. <https://doi.org/10.1023/A:1014743304566>
26. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606-13. <https://doi.org/10.1046/J.1525-1497.2001.016009606.X>
27. Coelho M, Ferreira JJ, Dias B, Sampaio C, Pavão Martins I, Castro-Caldas A. Assessment of time perception: the effect of aging. *J Int Neuropsychol Soc*. 2004;10(3):332-41. <https://doi.org/10.1017/S1355617704103019>
28. Mioni G, Stablum F, McClintock SM, Grondin S. Different methods for reproducing time, different results. *Atten Percept Psychophys*. 2014;76(3):675-81. <https://doi.org/10.3758/S13414-014-0625-3>
29. Block RA, Gruber RP. Time perception, attention, and memory: a selective review. *Acta Psychol (Amst)*. 2014;149:129-33. <https://doi.org/10.1016/J.ACTPSY.2013.11.003>
30. Wittmann M, Paulus MP. Decision making, impulsivity and time perception. *Trends Cogn Sci*. 2008 Jan;12(1):7-12. <https://doi.org/10.1016/J.TICS.2007.10.004>

Liraglutide Attenuates Gentamicin-Induced Nephrotoxicity in Rats by Reducing Oxidative Stress

Recep Burak Değirmen-tepe¹, Muammer Bozkurt², Osman Can², Mustafa Erkoç², Hazal Öztürk Gürgen³, Funda Yıldırım³, Fatih Hunç⁴, Fatma Ceyla Eraldemir⁴, Alper Ötünçtemur⁵

¹Urology Department, Sakarya University Training and Research Hospital, Sakarya, Türkiye

²Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Türkiye

³Department of Pathology, Istanbul University-Cerrahpasa, Faculty of Veterinary Medicine, Istanbul, Türkiye

⁴Department of Medical Biochemistry, Kocaeli University, Faculty of Medicine, Kocaeli, Türkiye

⁵Department of Urology, University of Health Sciences Okmeydani Training and Research Hospital, Istanbul, Türkiye

Submitted: 2024-03-06

Accepted: 2024-06-25

Correspondence

Recep Burak Degirmen-tepe, MD

Sakarya University Training and Research Hospital, Urology Department, P.C. 54050, Sakarya, Türkiye

E-mail: burakdegirmen-tepe@gmail.com

ORCID

R.B.D. [0000-0002-2875-5750](https://orcid.org/0000-0002-2875-5750)

M.B. [0000-0001-9011-7293](https://orcid.org/0000-0001-9011-7293)

O.C. [0000-0003-1329-6034](https://orcid.org/0000-0003-1329-6034)

M.E. [0000-0003-0679-2873](https://orcid.org/0000-0003-0679-2873)

H.O.G. [0000-0003-2748-6189](https://orcid.org/0000-0003-2748-6189)

F.Y. [0000-0003-0232-2081](https://orcid.org/0000-0003-0232-2081)

F.H. [0000-0001-6484-2432](https://orcid.org/0000-0001-6484-2432)

F.C.E. [0000-0001-9410-8554](https://orcid.org/0000-0001-9410-8554)

A.O. [0000-0002-0553-3012](https://orcid.org/0000-0002-0553-3012)

Abstract

Objective: Nephrotoxicity is a major complication of gentamicin (GEN), which is widely used in the treatment of severe Gram-negative infections. As we know, treatment with liraglutide has been shown to reduce oxidative stress. Therefore, we evaluated the potential protective effect of liraglutide against GEN-induced nephrotoxicity in rats.

Material And Methods: Twenty-eight rats were randomly divided into four groups: control group (Group 1); rats intraperitoneally injected with GEN (100 mg/kg/day; Group 2); rats treated with GEN plus distilled water (Group 3); and rats treated with GEN plus liraglutide (0.6 mg/kg/day; Group 4). After 15 days, the rats were sacrificed, their kidneys taken, and blood analysis performed. Tubular necrosis, interstitial fibrosis, and inducible nitric oxide synthetase (iNOS) scores were determined histopathologically in a part of the kidneys; malondialdehyde (MDA), reduced glutathione (GSH), E-cadherin and transforming growth factor β 1 (TGF- β 1) levels were determined in another part of kidneys.

Results: The GSH levels in renal tissue of only GEN-treated rats were significantly lower than others, and the administration of liraglutide to rats significantly increased the level of GSH. The group that was given GEN plus liraglutide had significantly lower MDA, TGF - β 1, and E - cadherin levels than that given GEN alone. The rats treated with GEN+liraglutide indicated less severe tubular necrosis and their glomeruli maintained a better morphology compared to the GEN group. iNOS expression was higher in the liraglutide administrated group than the group that applied only GEN.

Conclusion: Liraglutide exerts protective effects on GEN-induced kidney damage by reducing oxidative stress in rat model.

Keywords: gentamicin, liraglutide, kidney

Cite; Degirmen-tepe RB, Bozkurt M, Can O, Erkoç M, Öztürk G, Yildirim F, Hunç F, Eraldemir FC, Ötünçtemur A. Liraglutide Attenuates Gentamicin-Induced Nephrotoxicity in Rats by Reducing Oxidative Stress. New J Urol. 2024;19(2):68-77. <https://doi.org/10.33719/nju1447326>

INTRODUCTION

The kidney is a major organ that plays stunning roles in the human body. The primary duty of the kidney is to sustain the total body fluid volume, its composition, and acid-base balance. Many exogenous pollutants and chemical factors, including drugs, can alter kidney function(1). Gentamicin (GEN), a type of aminoglycoside, is used in the treatment of bacterial infections, but this drug is not renal parenchyma friendly. Nephrotoxicity, estimated to occur in approximately 10-20% of aminoglycoside treatments, is the most important complication of this drug (2) 40 mg/kg b.wt. Compared to the mitochondrial respiratory rates of 7 sham-control rats, State 3 (ADP dependent. Renal free radical production and accumulation causes glomerular congestion and the glomerular filtration rate decreases. This oxidative stress environment due to the rise of free radicals causes acute tubular necrosis(3).

Reactive oxygen species (ROS) are known to be significant mediators of GEN nephrotoxicity(4). In vitro and in vivo studies have shown that substances that reduce reactive oxygen metabolites are protective in GEN-induced renal failure(5). Lipid peroxidation (LPO) interfered with by ROS is a factor of cell destruction in various pathological conditions and indicates cellular damage which is widely used in the treatment of severe Gram-negative infections (6). Reactive oxygen species are important mediators of GEN-induced nephrotoxicity. Because of the strong antioxidant properties of pomegranate extract (PE). Moreover, the activation of proapoptotic and proinflammatory mediators would be stimulated by the superelevation of ROS, thus contributing to kidney damage induced by gentamicin (7).

Various pharmacological substances have been determined to have a potency in avoiding GEN-induced nephrotoxicity(8). Nevertheless, there is currently no clinically encouraging intervention to completely prevent or minimize the effect of GEN-induced nephrotoxicity. The medical world has been dealing with kidney protective antioxidant and anti-inflammatory treatments for a long time. The glucagon-like peptide-1 (GLP-1) analog liraglutide has been reported to reduce high glucose-induced oxidative stress, tumor necrosis factor (TNF) α , and inflammatory reaction in human endothelial cells(9). Inhibition of protein kinase C (PKC) translocation, nuclear factor (NF) κ B activation and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation contribute to the anti-inflammatory and anti-oxidative effects of liraglutide(10). Plasma reactive

oxygen compounds are an indicator of oxidative stress. Studies have shown that liraglutide provides significant reductions in plasma reactive oxygen compounds in patients with type 2 diabetes (11). There is also an anti-inflammatory effect of liraglutide. This effect has been demonstrated by experimental animal studies in the brains of rats with Alzheimer's disease and the hearts of diabetic rats (12).

Owing to these influences of liraglutide, in our study, the role of liraglutide in renal damage with GEN was investigated. In the present study, we aimed to find out whether liraglutide has any protective effect against GEN toxicity in an experimental animal study. Since there is no study investigating the protective effect of liraglutide against GEN-induced nephrotoxicity in the literature, our study is the first study on this subject.

MATERIAL AND METHODS

Rats

The experimental study was done on all 28 male Wistar-Albino rats, weighing between 200-300 gr. The rats were housed in clean plastic cages at 20-22°C constant temperature and in a humidity-controlled facility with a stable 12-hour light/dark cycle. During the experiment, the rats were given enough water and rat feed with free access. Ethics committee approval was obtained by applying to the Istanbul University Animal Experiments Local Ethics Committee before the experiment (Approval number: 06/06/2018-147577).

Medicaments

GEN (Gentreks, Bilim Pharmaceutical, Istanbul, Türkiye), and Liraglutide (Victoza®, Novo Nordisk, Plainsboro, New Jersey, USA) were purchased from a random pharmacy. GEN was injected intraperitoneally at a dose of 100mg/kg/day. Liraglutide was administered at a dose of 0.3 mg/kg every 12 hours subcutaneous injection.

Experimental Design

After a quarantine period of seven-day-long, 28 animals were indiscriminately divided into 4 even groups, every consisting of seven rats as follows: (1) control group; (2) GEN injected group for 14 consecutive days intraperitoneally (100 mg/kg/day); (3) GEN plus %0.9 saline-treated group for 14 consecutive days subcutaneously and (4) GEN plus liraglutide treated group (0.6 mg/kg/day liraglutide was administered immediately after injection of GEN) for 14 consecutive days. All rats were processed for 14 consecutive days. After 15 days, the rats were sacrificed by taking blood

from the heart under anesthesia, blood analysis performed, and their kidneys taken. Histopathologically, interstitial fibrosis scores and tubular necrosis were investigated in a part of renal tissues; E-cadherin, reduced glutathione (GSH), malondialdehyde (MDA), and transforming growth factor β 1 (TGF- β 1) levels were measured in another part of renal tissues. Sodium (Na⁺), potassium (K⁺), creatinine, and urea levels were measured as a part of blood analysis.

Biochemical Assays

On day 15, the rats were anesthetized by using xylazine/ketamine (10/50 mg/kg, i.p.) and killed. 24-hour urine collections were acquired in normal cages one day before the rats were killed. Kidney tissues were split into 2 pieces for microscopic inspection and biochemical analysis. Blood was taken from the hearts of rats and Na⁺, K⁺, urea, and creatinine levels were measured. MDA, reduced GSH, E-cadherin, and Transforming growth factor beta-1 (TGF- β 1) were measured in the renal cortical tissues. For the determination of MDA and GSH in rat kidney tissue, the tissues were weighed, 1/20 (weight/volume) phosphate buffer saline was added (0.1 M / pH 7.4), and homogenized with a tissue homogenizer. Homogenates were centrifuged at 3500rpm for 15 minutes, the supernatants were separated and stored at -80 ° C until the time to be analyzed. MDA levels were assayed spectrophotometrically. MDA is referred to as thiobarbituric acid reagent. MDA was measured with thiobarbituric acid at 532 nm. In the measurement of GSH, the method based on the use of Ellmann's reagent was used and spectrophotometrically measured. Serum creatinine and urea levels were measured by using Beckman Coulter diagnostic kits. Na⁺ and K⁺ values were measured by ion-selective electrode method using Beckman Coulter AU5821 autoanalyzer.

Histopathological Examinations

Veterinary pathologist performed the evaluations. Kidney tissue samples obtained from rats were routinely processed, embedded in paraffin blocks, and cut in a manual rotary microtome (Leica RM2255). Sections were investigated under a light microscope (Olympus BX50) after being stained with Hematoxylin & Eosin (H&E). Histopathological evaluation was made according to the degree of tubular damage and the intensity of inflammatory cell infiltration. If tubular damage is less than 25%, mild (1); If the affected tubule ratio is 25-50%, it is medium (2); If more than 50%, it is scored as severe (3). To evaluate inflammatory cell infiltration, 5 random areas were selected at 40x magnification for each kidney section, and

scoring for neutrophils and mononuclear leukocytes were done separately. We used Masson's trichrome to assess the degree of interstitial fibrosis. The interstitial area was stained green with Masson's trichrome. Then, an image analyzer was then used (Leica; Leica Micros Imaging Solutions, Cambridge, UK), and 5 pieces were randomly selected from any kidney sample and analyzed. After that, the Banff classification was used to score the degree of interstitial fibrosis and mononuclear cell infiltration (13).

Immunohistochemical Staining

All immunohistochemical evaluations were done double-blinded. Kidney sections taken on positively charged slides for immunohistochemical (IHC) labeling with inducible nitric oxide synthetase (iNOS) primary antibody were stained following the manufacturer's instructions from which the antibody was supplied. Deparaffinized sections were passed through 100, 96, 80, and 70% alcohol series and distilled water, respectively. Heat treatment was applied with citrate buffer solution (pH 6.0) in a microwave oven for 20 minutes at 750W. Then, it was incubated for 10 minutes with a 0.3% hydrogen peroxide solution in methanol to block the endogenous peroxidase activity. Anti-iNOS (PA516855, 1/100 dilution, Invitrogen) antibody was then applied to the sections that were kept at room temperature for 10 minutes by dropping the protein block solution in a humid cabinet and incubating for 90 minutes at room temperature. After the primary antibody incubation, the reaction was completed with a secondary antibody kit (Expose Mouse and Rabbit Specific HRP / DAB Detection IHC Kit, Cat no. Ab80436, Abcam) based on the micro polymer principle. The sections were incubated at room temperature for 10 minutes with Horseradish Peroxidase (HRP) conjugated secondary antibody. It was labeled with diaminobenzidine (DAB). Floor painting with Mayer hematoxylin has been completed. Sections were washed with Tween 20-added phosphate buffer solution (pH 7.4) after all incubation steps until background staining, except between protein blocking and primary antibody steps. IHC staining was examined with a light microscope and the immune reaction was scored according to the ratio of marked tubular epithelial cells and the intensity of staining. If the rate of marked tubular epithelial cells is 0% (0); Light up to 30% (1); 30-60% medium (2); If more than 60%, it was determined as severe (3). Positive reaction intensity was rated as, no reaction (0); light (1); medium (2); severe (3). The final score is determined by multiplying these two scores. Results are expressed as negative (0); mild (1-3); medium (4-6); and strongly positive

(7-9)(14).

Statistical Analysis

The p-value of < 0.05 was accepted as statistically significant. Continuous variables of entire groups were indicated as mean values \pm standard deviation (SD). The distribution was examined with the Shapiro-Wilk test. Histopathological data were evaluated using the chi-square test. Biochemical data were analyzed using the Kruskal-Wallis test. In the case of statistical significance between groups, the Mann-Whitney U test was used to determine whether it was significant for the two groups. Bonferroni adjustment for multiple comparisons was applied. $P < 0.0083$ was considered to indicate a significant difference, since the number of groups was four, and the significance level was 5%.

RESULTS

There were no signs of death or visible toxicity in the rats. The biochemical, histopathological, and immunohistochemical outcomes were analogous for the control and liraglutide-treated groups, therefore, we determined to evaluate them indiscriminately and to declare only the control group.

Urinary Volume

It was observed that the highest amount of urine was collected from the GEN-treated rats. This was statistically significant ($p < 0.01$). This indicated the presence of GEN-induced polyuria. There was no difference in the liraglutide injected group compared to the control group, pointing out the preventive effect of liraglutide towards ATN (Table 1).

Biochemical Variables

The urea and creatinine values were found to be statistically significantly higher in the group of rats treated with GEN alone ($p < 0.05$). With the addition of Liraglutide to the treatment of rats under GEN, a decrease in serum urea and creatinine levels was observed. Na^+ and K^+ values among the four groups had similarities (Table 1).

When MDA and GSH values were calculated, it was observed that the MDA value in the 4th group and the GSH value in the 3rd group were significantly lower than the other groups ($p < 0.05$). Application of liraglutide after GEN treatment provided a statistically significant increase in GSH values ($p < 0.05$). When E-cadherin and TGF - $\beta 1$ values were evaluated, it was observed that they were increased in the group treated with GEN. These values were statistically significant when compared with the control group. TGF - $\beta 1$ and E - cadherin

values decreased significantly after liraglutide injection ($p < 0.05$). The details are shown in Table 2.

Histopathological and Immunohistochemical Results

While mild tubular damage such as granular and vacuolar degeneration was observed in the tubular epithelium in animals belonging to the control group (Figure 1), neutrophil or mononuclear cell infiltration was not detected in the intertubular, interstitial, and perivascular areas. Moderate and severe tubular necrosis, degeneration, dilatation, vacuolization in the tubular epithelium, epithelial hyperplasia, and mild interstitial and perivascular mononuclear cell infiltration were observed in the 2nd and 3rd groups. In the comparison between groups in Table-3, it was seen that tubular necrosis and interstitial fibrosis were more severe in the groups given GEN. In the group given GEN+Liraglutide, a similar histopathological appearance was observed in the control group. Leukocyte infiltration and iNOS were observed to be more severe in the groups that intervened with GEN, and when liraglutide was added to the treatment, similar results were obtained in the control group. (Figure 2 and Figure 3) (Table 3 and Table 4). Epithelial hyperplasia and mononuclear inflammatory cells were observed in the kidney tissues after liraglutide treatment. There was a decrease in the number of degenerative tubules and mononuclear inflammatory cells (Figure 4).




Figure 1. Degenerated, swollen, and granular-looking tubular epithelium (arrows), control group, Bar = 50 μm , H&E

Table 1. Effects of GEN alone and its combination with liraglutide on plasma urea, creatinine, Na⁺, K⁺, and 24-h urine volume levels in rats.

Parameters	Control (Group 1)	GEN (Group 2)	GEN+Ve (Group 3)	GEN+Liraglutide (Group 4)
Urea (mg/dl)	34±7,1	102±10,3 ^a	101±5,1	42±10,2 ^b
Creatinine (mg/dl)	0,42±0,1	1,89±0,9 ^a	1,83±1,2	0,72±0,4 ^b
Na ⁺ (mmol/L)	138±1,2	139±2,5	138,2±1,3	137±1,6
K ⁺ (mmol/L)	3,9±0,3	3,9±0,9	4±0,5	3,9±0,2
24-h urine volume (ml)	8,8±1,2	20,3±3,7 ^a	21,1±3,2	8,9±1,9 ^b

Notes: Values are expressed as mean±SD for seven rats in each group.

Groups: Control, GEN (gentamicin), GEN+Ve (gentamicin+vehicle), GEN+liraglutide(gentamicin+liraglutide)

^aSignificantly different from the control.

^bSignificantly different from the gentamicin group (p<0.05).

Table 2. Effects of liraglutide on rat kidney MDA, GSH, E-cadherin, and TGF-β1 levels.

Parameters	Control (Group 1)	GEN (Group 2)	GEN+Ve (Group 3)	GEN+Liraglutide (Group 4)
MDA (μM/mg)	16,5±5,8	26,4±4,3 ^a	24,3±2,5	18±4,5 ^b
GSH (μg/mg)	3,1±2	2±0,5 ^a	1,81±0,9	2,9±0,7 ^b
E-cadherin (ng/mg)	0,5±0,2	1,5±0,1 ^a	1,5±0,3	0,6±0,3 ^b
TGF-β1 (pg/mg)	2,5±0,7	8±1,7 ^a	7,6±2,4	3,3±0,5 ^b

GSH: reduced glutathione

MDA: malondialdehyde

TGF-β1: transforming growth factor β1

Notes: Values are expressed as mean±SD for seven rats in each group

^aSignificantly different from the control.

^bSignificantly different from the gentamicin group (p<0.05)

Table 3. Semiquantitative analysis of tubular necrosis, interstitial fibrosis in control, GEN, GEN + Ve, and GEN + liraglutide groups.

	Tubular necrosis					Interstitial fibrosis			
	n	none	+	++	+++	none	+	++	+++
Control	7	6	1	0	0	6	1	0	0
GEN	7	0	1	2	4	0	1	0	6
GEN + Ve	7	0	0	1	6	0	0	0	7
GEN + liraglutide	7	1	3	3	0	4	1	1	1

n: total number of rats each group , +: mild , ++: moderate , +++: severe tubular necrosis and interstitial fibrosis reported

Acute inflammation findings such as tubuler necrosis and interstitial fibrosis were highest in the ischemia-reperfusion group compared to the other groups.

Table 4. Comparison of leukocyte infiltration and iNOS between groups

	Leukocyte infiltration					iNOS			
	n	none	+	++	+++	none	+	++	+++
Control	7	6	1	0	0	2	2	2	1
GEN	7	0	1	2	4	1	3	2	1
GEN + Ve	7	0	0	2	5	1	2	3	1
GEN + liraglutide	7	2	3	2	0	1	1	4	1

n: total number of rats each group , +: mild , ++: moderate , +++: severe positivity fibrosis reported




Figure 2. Degenerated, swollen, and granular-looking tubular epithelium, coarse nucleus structure (arrow), GEN group Bar = 20 μm, H&E




Figure 4. Epithelial hyperplasia areas (arrow), mononuclear inflammatory cells (stars), Gentamicin + Liraglutide group, Bar = 20 μm, H&E.




Figure 3. Degenerative tubules (stars), mononuclear inflammatory cells (arrow), GEN group, Bar = 20 μm, H&E




Figure 5. Slight anti-iNOS positive reaction, Control group, Bar = 50 μm, IHC

Varying degrees of positive reaction were found in all groups, including the control group in the immunohistochemical analysis (Figure 5). An anti-iNOS immune positive reaction was observed especially in proximal tubular epithelium. The reaction was rarely observed in the glomerular area. Especially in the gentamicin-applied group, since tubular damage was more severe than in the other groups (Figure 6), the immune reaction was found less due to the absence or necrosis of the epithelium. Tubular damage was moderate in group 4. iNOS expression was higher in group 4 than in the group that was applied only gentamicin (Table 4).




Figure 6. Strong positive anti-iNOS reaction showing intensity in proximal tubules, Gentamicin group, Bar = 50 μm, IHC




Figure 7. Widespread strong positive anti-iNOS reaction, liraglutide treated group, Bar = 20 μm, IHC

DISCUSSION

The kidneys are sensitive to damage from drugs. Aminoglycosides are one of the antibiotics with proven efficacy against gram-negative bacteria and are used clinically in daily practice, but nephrotoxicity may occur in its use. The tubular effect, triggered by drug accumulation in epithelial tubular cells, constitutes a major part of GEN-induced AKI. Ultimately, gentamicin causes acute tubular necrosis by causing glomerular obstruction, free radical production in the kidney, and decreased antioxidant protection mechanisms which may range from a mere loss of the brush border in epithelial cells to an overt tubular necrosis (15). Tubular cytotoxicity is the consequence of many interconnected actions, triggered by drug accumulation in epithelial tubular cells. Accumulation results from the presence of the endocytic receptor complex formed by megalin and cubulin, which transports proteins and organic cations inside the cells. Gentamicin then accesses and accumulates in the endosomal compartment, the Golgi and endoplasmic reticulum (ER). The use of certain antioxidant agents to reduce or prevent the effect of GEN nephrotoxicity is a reasonable consideration owing to the clear burden of ROS in GEN-induced kidney injury 40 mg/kg b.wt. Compared to the mitochondrial respiratory rates of 7 sham-control rats, State 3 (ADP) dependent (2).

Recently, it has been started to share data that liraglutide reduces oxidative stress caused by high glucose level and tumor necrosis factor (TNF) - α , in endothelial cells(9). Inhibition of PKC translocation, NADPH oxidase activation, and NF- κ B activation contribute to the anti-inflammatory and anti-oxidative effects of liraglutide(10). Besides, liraglutide reduces the levels of plasma reactive oxygen metabolites, one of the important indicators of oxidative stress (11).

The understanding of GEN nephrotoxicity is quite important clinically; such as in the presence of 1-2 liter urine output per day, an oliguric acute renal failure nephrotoxicity, which can be seen with azotemia(16). In the present study, the significant finding indicating the presence of polyuria due to GEN was that the 24-hour urine volume in the GEN group was the highest amount, while it was not different in the group treated with GEN + liraglutide. It showed the protective role of liraglutide against ATN. Measured creatinine and urea levels after treatment with GEN reflected kidney damage. Normalization of serum creatinine and urea levels after liraglutide administration showed that liraglutide restored renal function by protecting renal cells against the

GEN challenge. In this study, MDA levels, i.e. the indicators of lipid peroxidation of the membranes as a result of oxidative damage as well as both nuclear and mitochondrial DNA (17). Melatonin achieves this widespread protection by means of its ubiquitous actions as a direct free radical scavenger and an indirect antioxidant. Thus, melatonin directly scavenges a variety of free radicals and reactive species including the hydroxyl radical, hydrogen peroxide, singlet oxygen, nitric oxide, peroxynitrite anion, and peroxynitrous acid. Furthermore, melatonin stimulates a number of antioxidative enzymes including superoxide dismutase, glutathione peroxidase, glutathione reductase, and catalase. Additionally, melatonin experimentally enhances intracellular glutathione (another important antioxidant, were significantly increased after GEN administration. In parallel with this, GSH levels decreased in the renal tissue after GEN administration. GSH plays an important role in protecting the lipid and protein integrity in the cell membrane, as well as providing great protection from oxidative damage by participating in cellular defense systems (18). In the group treated with GEN+liraglutide, we found decreased MDA levels and increased GSH levels.

iNOS can be produced and detected by inducing secondary messengers in the inflammatory infection process(19). Particularly in the gentamicin-applied group, since tubular damage was more severe than the other groups, the immune reaction was found less due to the absence or necrosis of the epithelium in this study. iNOS expression was higher in the group treated with GEN + liraglutide than in the GEN group. Fibrosis and progressive tubular damage in the renal cortex have been demonstrated in previous studies. In our study, necrosis, degeneration, dilatation, and vacuolization of the tubular epithelium were evaluated histopathologically. All these were most severe in the GEN-treated group. This damage suggested that ROS formed as a result of oxidative stress caused by GEN. The kidney samples of the liraglutide-treated group had quite normal histological features except for slight desquamation and atrophy of the tubular epithelial cells. These findings strongly indicate that liraglutide may have a protective effect against the kidney from GEN-induced injury by improving the oxidant status.

Experimental animal studies are very important in establishing a new treatment modality as they provide the basis for clinical studies. To administer a drug to a person in a pathological situation, several stages are required. Experimental animal studies are one of these stages. In our

study, a limited number of data were examined, so it would not be correct to obtain a definite result from a single study, however, when the data obtained from similar experimental studies are evaluated together, a basis for clinical studies can be formed.

This study had some limitations no evidence of long-term effects, the small sample, and the amount of biochemical and histopathological data examined is limited. Besides evaluated morphological semi-quantitative results, quantitative methods were not performed in the present study.

CONCLUSION

The results reported here indicate that liraglutide exerts antioxidant, anti-inflammatory and, antifibrotic effects on GEN-induced renal injury in rats by reducing oxidative stress. The observed protective effects can be attributed to the antioxidant properties of liraglutide. This study can be a good base for more studies aimed at finding the best therapy for this kind of pathology. Even if liraglutide could be protective against renal damage of GEN, it needs further research in larger animal groups.

Conflicts of interest: Authors have no conflicts of interest. The authors have nothing to disclose.

Funding: No funding was used.

Ethical Approval: Ethics committee approval was obtained by applying to the Istanbul University Animal Experiments Local Ethics Committee before the experiment (Approval number: 06/06/2018-147577). The study protocol conformed to the ethical guidelines of the Helsinki Declaration.

Author Contributions: Conception and design: Degirmentepe RB, Bozkurt M, Data acquisition: Otunctemur A, Yildirim F, Data analysis and interpretation: Erkok M, Can O, Drafting the manuscript: Degirmentepe RB, Critical revision of the manuscript for scientific and factual content: Gergen Ozturk H, Eraldemir FC, Hunc F Statistical analysis: Degirmentepe RB

REFERENCES

1. Otunctemur A, Ozbek E, Cekmen M, Cakir SS, Dursun M, Polat EC, et al. Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative

- damage in rat kidney. *Renal Failure*. 2013;35(3):403–10. <https://doi.org/10.3109/0886022X.2012.761040>
2. Simmons CF, Bogusky RT, Humes HD. Inhibitory effects of gentamicin on renal mitochondrial oxidative phosphorylation. *Journal of Pharmacology and Experimental Therapeutics*. 1980;214(3):709–15.
 3. Hur E, Garip A, Camyar A, Ilgun S, Ozisik M, Tuna S, et al. The effects of vitamin D on gentamicin-induced acute kidney injury in experimental rat model. *International Journal of Endocrinology*. 2013;2013. <https://doi.org/10.1155/2013/313528>
 4. Banday AA, Farooq N, Priyamvada S, Yusufi ANK, Khan F. Time dependent effects of gentamicin on the enzymes of carbohydrate metabolism, brush border membrane and oxidative stress in rat kidney tissues. *Life Sciences*. 2008;82(9–10):450–9. <https://doi.org/10.1016/j.lfs.2007.11.014>
 5. Pedraza-Chaverrí J, Maldonado PD, Medina-Campos ON, Olivares-Corichi IM, Granados-Silvestre MDLÁ, Hernández-Pando R, et al. Garlic ameliorates gentamicin nephrotoxicity: Relation to antioxidant enzymes. *Free Radical Biology and Medicine*. 2000;29(7):602–11. [https://doi.org/10.1016/s0891-5849\(00\)00354-3](https://doi.org/10.1016/s0891-5849(00)00354-3)
 6. Cekmen M, Otunctemur A, Ozbek E, Cakir SS, Dursun M, Polat EC, et al. Pomegranate extract attenuates gentamicin-induced nephrotoxicity in rats by reducing oxidative stress. *Renal Failure*. 2013;35(2):268–74. <https://doi.org/10.3109/0886022X.2012.743859>
 7. Dursun M, Sahin S, Besiroglu H, Otunctemur A, Ozbek E, Cakir SS, et al. Protective effect of nebivolol on gentamicin-induced nephrotoxicity in rats. *Bratislava Medical Journal*. 2018;119(11):718–25. <https://doi.org/10.4149/BLL.2018.128>
 8. Balakumar P, Rohilla A, Thangathirupathi A. Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it? Vol. 62, *Pharmacological Research*. 2010. p. 179–86. <https://doi.org/10.1016/j.phrs.2010.04.004>
 9. Shiraki A, Oyama J ichi, Komoda H, Asaka M, Komatsu A, Sakuma M, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF- α -induced oxidative stress and inflammation in endothelial cells. *Atherosclerosis*. 2012;221(2):375–82. <https://doi.org/10.1016/j.atherosclerosis.2011.12.039>
 10. Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, et al. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. *Atherosclerosis*. 2014;232(1):156–64. <https://doi.org/10.1016/j.atherosclerosis.2013.10.025>
 11. Okada K, Kotani K, Yagyu H, Ando A, Osuga J ichi, Ishibashi S. Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus. Vol. 47, *Endocrine*. 2014. p. 962–4.
 12. Parthasarathy V, Hölscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. *European Journal of Pharmacology*. 2013;700(1–3):42–50. <https://doi.org/10.1016/j.ejphar.2012.12.012>
 13. Kinugasa F, Noto T, Matsuoka H, Urano Y, Sudo Y, Takakura S, et al. Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. *Transplant Immunology*. 2010;23(1–2):18–23. <https://doi.org/10.1016/j.trim.2010.02.003>
 14. Buyuklu M, Kandemir FM, Ozkaraca M, Set T, Bakirci EM, Topal E, et al. Beneficial effects of lycopene against contrast medium-induced oxidative stress, inflammation, autophagy, and apoptosis in rat kidney. *Human and Experimental Toxicology*. 2015;34(5):487–96. <https://doi.org/10.1177/0960327114542964>
 15. Quiros Y, Vicente-Vicente L, Morales AI, López-Novoa JM, López-Hernández FJ. An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. *Toxicological Sciences*. 2011;119(2):245–56. <https://doi.org/10.1093/toxsci/kfq267>
 16. Silan C, Uzun Ö, Çomuno lu NÜ, Gokçen S, Bedirhan S, Cengiz M. Gentamicin-induced nephrotoxicity in rats ameliorated and healing effects of resveratrol. *Biological and Pharmaceutical Bulletin*. 2007;30(1):79–83. <https://doi.org/10.1248/bpb.30.79>
 17. Reiter RJ, Acuña-Castroviejo D, Tan DX, Burkhardt S. Free radical-mediated molecular damage: Mechanisms for the protective actions of melatonin in the central nervous system. In: *Annals of the New York Academy of Sciences*. 2001. p. 200–15.
 18. Ross D. Glutathione, free radicals and chemotherapeutic agents. *Mechanisms of free-radical induced toxicity*

and glutathione-dependent protection. *Pharmacology and Therapeutics*. 1988;37(2):231–49. [https://doi.org/10.1016/0163-7258\(88\)90027-7](https://doi.org/10.1016/0163-7258(88)90027-7)

19. Chamberlain CG, Mansfield KJ, Cerra A. Nitric oxide, a survival factor for lens epithelial cells. *Molecular Vision*. 2008;14:983–91.

Metabolic Risk Factors in Children with Urinary System Stones

Mahmut Çivilibal¹, Ata Mert Çivilibal², Mesrur Selçuk Sılay³

¹ Department of Pediatrics, Division of Pediatric Nephrology, Memorial Bahçelievler Hospital, İstanbul, Türkiye

² School of Medicine Student, Bezmialem Foundation University, İstanbul, Türkiye

³ Department of Urology, Division of Pediatric Urology, School of Medicine, Biruni University, and Memorial Bahçelievler Hospital, Türkiye

Submitted: 2024-05-31

Accepted: 2024-06-27

Correspondence

Mahmut Çivilibal, MD

Department of Pediatrics,
Memorial Bahçelievler Hospital,
Bahçelievler mah. Adnan Kahveci
Bulvarı. No:227 Bahçelievler,
İstanbul Türkiye.

E-mail: drcivilibal@hotmail.com

ORCID

M.Ç. [0000-0002-0381-8145](https://orcid.org/0000-0002-0381-8145)

A.M.Ç. [0009-0008-3338-6495](https://orcid.org/0009-0008-3338-6495)

M.S.S. [0000-0001-5091-9654](https://orcid.org/0000-0001-5091-9654)

Abstract

Objective: To diagnose, treat, and prevent stone recurrence, it is important to determine the metabolic risk factors that play a role in developing urinary system stone disease in children. This study assessed children with urinary system stones' clinical, radiological, and metabolic characteristics.

Material And Methods: A retrospective study was conducted on the records of pediatric patients who applied to our pediatric outpatient nephrology clinic for various reasons between February 2018 and December 2023 and were diagnosed with urinary system stones.

Results: Of the 122 patients with a mean age of 4.40 ± 4.16 years (1 month-17 years), 63 (51.6%) were boys and 59 (48.4%) were girls. In 61.4% of the children, a family history was identified. The most common presenting symptom was abdominal/flank pain or restlessness (47.5%). In 25.4% of the patients, the stones were ≤ 3 mm (microlithiasis), and most stones were in the upper system. One or more metabolic abnormalities have been detected during urine analysis for 58.2% of patients. The most frequent metabolic abnormalities were hypercalciuria (20.5%) and hypocitraturia (17.2%). In 74.6% of patients, the size of stones decreased or completely disappeared with medical treatment based on underlying metabolic abnormalities, and in 17.2%, they did not change at all. Only eight (6.6%) patients required interventional procedures.

Conclusion: Metabolic causes should be investigated first in all children with urinary tract stones. Special medical treatments designed to alter metabolism reduce the need for invasive stone procedures.

Keywords: Childhood, Urinary System Stone, metabolic risk factors, hypercalciuria, hypocitraturia

INTRODUCTION

Urinary system stones are abnormal mineral accumulations anywhere in the urinary system, especially the kidneys. Although it is less common in children than adults, it is common in all ages, including infancy, and is increasingly prevalent (1). It is influenced by prevalence, age, gender, climate conditions, dietary habits, genetic and socio-economic factors, between 1% and 5% in developed countries and between 5% and 15% in developing countries. In adults, it is more common in males, while in children, there is no pronounced male predominance (2). Our country is in an endemic stone range extending from the Balkans to India.

Stone formation is the formation of crystals due to cell degradation at the tubular level for various physical and biochemical reasons. Some underlying anatomical problems that facilitate the development of stones (such as urinary system constraints and vesicoureteral reflux), infections, endocrine, or some metabolic disorders are detected in 75 to 85 percent of affected children (3,4). The vast majority of stones in children are the result of one or more metabolic disorders. An increase in lithogenic solutes such as calcium, oxalate, uric acid, and cystine in the urine and/or a decrease in factors that inhibit stone formation, such as citrate, magnesium, and pyrophosphate, lead to urinary system stones (5-7).

This study aimed to evaluate the clinical, demographic and radiological findings of children diagnosed with urinary system stones in our center and to determine the metabolic causes that cause stones

MATERIAL AND METHODS

The study retrospectively examined the records of 122 children aged 0-18 referred to our pediatric nephrology clinic for various reasons between February 2018 and December 2023. This study was approved by the Local Ethics Committee (decision no: 114, date: 25.01.2024). It was carried out under the principles of the current Declaration of Helsinki and the principles of good clinical practice. The patient's age, gender, age at diagnosis, complaints, and symptoms at presentation, family history of stones, physical examination findings, medications radiological and laboratory findings were obtained from hospital records. Those with endocrine or metabolic disorders were excluded.

During the application period, the urinary system was evaluated by ultrasonography or plain abdominal

radiography, which evaluated the location, size, and any anatomical problems of the stone. Stones >3mm in size were defined as urolithiasis, and hyperechoic structures ≤3mm in diameter in the renal calyces were defined as microlithiasis.

To determine the cause of stones, blood urea nitrogen (BUN), creatinine (Cr), sodium (Na), potassium (K), chlorine (Cl), calcium (Ca), phosphorus (P), magnesium (Mg), uric acid, Parathormone, vitamin D, venous blood gases, complete urine analysis and urine culture results were examined. To determine metabolic risk factors that may predispose to stone development, calcium, uric acid, oxalate, cystine, citrate, magnesium, and creatinine levels in spot urine were evaluated and recorded. The metabolites studied from the spot urine sample were standardized by dividing by the urine creatinine level. The results were evaluated according to the values previously stated in the literature (3,8).

Statistical Analysis

Statistical analyses of the study were performed with the Statistical Package for Social Sciences (SPSS), version 26.0 for Windows (SPSS Inc. Chicago, USA) computer package program. Compliance of continuous variables with normal distribution was evaluated using Kolmogorov-Smirnov/Shapiro-Wilk tests. Variables with normal distribution were given as mean±standard deviation (SD), and variables without normal distribution were given as median (minimum-maximum). Frequency variables were expressed as number (n) and percentage (%). The statistical significance level was accepted as P<0.05.

RESULTS

Of the 122 patients who underwent metabolic analysis with the diagnosis of urinary system stone disease, 51.6% (n=63) were male, and 48.4% (n=59) were female, and it was determined that there was no gender difference between the patients (p>0.05). The average age at first detection of the stone was 4.40±4.16 years, the age distribution was 1 month-17 years, and the average age of the study period was 5.44 ± 4 years.

Table 1 presents the patients' demographic characteristics and admission findings. Most of the patients (61.4%) had a family history of kidney stones. The most common reason for admission (47.5%) was abdominal/flank pain or restlessness. While restlessness was the most common reason for admission in patients aged five and younger, it was abdominal and/or side pain in patients older than five

years. Urinary system stones were detected incidentally in 11 patients (9%) who had no symptoms suggestive of stones.

In 25.4% of the patients, the stones were ≤ 3 mm (microlithiasis), and most stones were in the upper system (Table 2). It was determined that there was a significant relationship between stone size and admission findings, such as hematuria and urinary tract infection ($p < 0.05$). It was determined that 68.9% ($n=84$) of the patients had one stone in their urinary system, and 31.1% ($n=38$) had more than one stone. In our study, mild biochemical abnormalities were detected in a few patients. Three patients (2.5%) had mild hypercalcemia, two patients (1.6%) had mild metabolic acidosis, and one patient (0.8%) had mild metabolic alkalosis. Metabolic disorder was detected in the urine examination of 58.2% of all patients ($n=71$) (Table 3). While a single metabolic disorder was detected in 65 patients, six patients had more than one metabolic disorder. The most common metabolic cause in our patients was hypercalciuria (20.5%), the second most common was hypocitraturia (17.2%), followed by hyperoxaluria, hyperuricosuria, cystinuria, and hypomagnesuria, respectively.

With medical treatments in addition to adequate fluid intake and salt reduction, the stones in approximately 74.6% (91/122) of the patients shrank or disappeared completely, and the size of 17.2% did not change (Table 4). Stone sizes at the first diagnosis period in patients whose stones disappeared or decreased in size were smaller than in patients whose stones did not disappear. The most common metabolic disorder in these patients was determined to be hypocitraturia (34.1%).

Extracorporeal shock wave lithotripsy (ESWL) was applied to three patients out of a total of eight patients who developed an increase in stone size and/or obstruction in the urinary system due to stones despite medical monitoring and treatments. Stones were removed surgically in three of the other five patients by endourological methods and in two by percutaneous nephrolithotomy. Calcium oxalate stones were detected in five (62.5%) of eight patients, cystine stones were detected in two (25%), and uric acid stones were detected in one (12.5%) of the eight patients who underwent stone analysis.

Table 1. Demographic characteristics of the patients and admission findings

	Number of patients (n)	Ratio (%)
Male/female	63/59	51.6/48.4
Family history of stones	75	61.4
Age distribution at admission		
<1 year	36	29.5
1-5 years	53	43.5
5-10 years	21	17.2
>10 years	12	9.8
Admission findings		
Abdominal/flank pain/restlessness	58	47.5
Urinary tract infection	24	19.7
Vomiting	15	12.3
Hematuria	14	11.5
Incidental	11	9.0

Table 2. Radiological findings of patients

	Number of patients (n)	Ratio (%)
Size of stone		
≤ 3 mm	31	25.4
> 3 mm	91	74.6
Location of the stone		
Left kidney	40	32.8
Right kidney	33	27.0
Both kidneys	29	23.8
Ureter	12	9.8
Kidney and ureter	8	6.6
Urinary system anomaly		
Hydronephrosis	11	9.0
Horseshoe kidney	1	0.8
Ectopic kidney	1	0.8
Ureterocele	1	0.8

Table 3. Urinary metabolic abnormalities in patients

	Number of patients (n)	Ratio (%)
Patients with metabolic abnormalities	71	58.2
Single metabolic abnormality	65	53.3
Hypercalciuria	25	20.5
Hypocitraturia	21	17.2
Hyperoxaluria	10	8.2
Hyperuricosuria	6	4.9
Cystinuria	2	1.6
Hypomagnesiuria	1	0.8
Multiple metabolic abnormality	6	4.9
Hypercalciuria + Hyperuricosuria	3	2.5
Hypercalciuria + Hypocitraturia	2	1.6
Hypocitraturia + Hyperuricosuria	1	0.8

Table 4. Treatment and follow-up results of patients

Results	Number of patients (n)	Ratio (%)
Patients with no stones detected	68	55.7
Decrease in stone size	23	18.9
Patients whose stone size does not change	21	17.2
Increase in stone size	10	8.2

DISCUSSION

Although urinary system stone disease is relatively less common in children than adults, its frequency has increased in recent years. While a sedentary lifestyle, changing eating habits and inappropriate vitamin use play an important role in this increase, the widespread use of ultrasonography and increased awareness about stones have made diagnosis easier and more frequent (9).

The frequency, etiology, type, content, and location of urinary system stones are associated with geography. The incidence varies worldwide; It is most frequently seen in endemic regions such as Türkiye and Thailand (10). It has been reported that there is a genetic predisposition to the development of urinary system stones and that half of the children with stones have a family history of stones (11). In this study, a family history of stones was found to have a frequency of 61.4%, consistent with the literature.

Urinary system stones are more common in males in adulthood. Male dominance has also been reported in some child studies (12). However, consistent with our study, it is accepted that there is no gender difference in childhood (13,14). In the present study, 51.6% (n=63) of 122 patients were male, and 48.4% (n=59) were female, and there was no statistical gender difference.

Complaints and findings of the patients at admission vary depending on the age of the patient, the location and size of the stone and whether it causes obstruction, the presence of accompanying urinary tract infection (UTI), and the presence of underlying structural or functional genitourinary anomalies (12-15). The most common symptom in children with urinary system stones is flank or abdominal pain. Infants and young children often cannot express the existence, location, and severity of pain and usually present with nonspecific complaints such as restlessness. Apart from pain or restlessness, these patients may experience hematuria, dysuria, urgency symptoms suggestive of UTI, and nausea/vomiting (16). Fifteen to 20% of children with urinary tract stones are asymptomatic, mainly young children whose stones are detected when abdominal imaging is performed for other purposes (17). In our study, 9% of the patients were children whose stones were detected incidentally while examined for another reason. The most common complaints in our remaining patients were abdominal pain, side pain, or restlessness; clinical findings suggestive of urinary tract infection (or history of UTI); nausea/vomiting; and hematuria. The presenting symptoms of our patients were similar to those in previously reported pediatric studies (13,14,18,19).

Twenty to 25% of children with urinary tract stones have a urinary tract infection or a history of infection. Infection may be the primary cause of a stone or may occur along with an underlying urinary metabolic or structural abnormality. Functional or anatomical obstructions of the urinary tract predispose to stasis and infection, possibly encouraging stone formation. Advances in early detection and repair of obstructive uropathies have reduced the incidence of stones due to infections. In this study, one-fifth of the patients had a history of active or previous urinary tract infections at admission, but no one had struvite stones.

Similar to previous studies, our study observed that most urinary system stones (83.6%) were in the upper urinary system (13,14,18,19). None of our patients had bladder stones.

The decrease in the incidence of bladder stones is attributed to changes in eating habits.

In addition to detecting urinary system stones, ultrasonography provides the advantage of anatomical evaluation. In case series of children with urinary tract stones, structural abnormalities (such as hydronephrosis, double collecting system, posterior urethral valve, and bladder anomalies) have been reported in 10 to 25 percent of patients (14,15). Congenital and structural abnormalities accompanied by urinary stasis are associated with kidney stones. Urine stasis paves the way for crystal and stone formation. This study detected structural urinary system anomalies in 14 children (11.4%). Studies from our country reported 3 to 20% of urinary system anomalies (13,14,18).

Most urinary tract stones in children are associated with one or more metabolic disorders. It is important to reveal the underlying metabolic causes in order to apply an effective treatment method. Metabolic studies consist of blood and urine analyses. Hypercalcemia, hyperuric acidemia, high vitamin D, hyperparathyroidism, metabolic acidosis, or alkalosis can be informative in revealing some diseases that may cause urinary system stones. These results guide the diagnosis, diet, and drug treatments of primary diseases (such as renal tubular diseases).

Metabolic etiology in adults is not as common as in children. For this reason, while metabolic evaluation is recommended only for those with recurrent stones in adults, it is recommended when the first stone is detected in children (7,8). The basis of metabolic assessment is measuring the amounts of solutes in the urine that predispose to stone formation. This is calculated by measuring their amounts in 24-hour urine or by the ratio of each solute to creatinine in spot urine and comparing them with normal age (13,14,18,19). In this study, metabolic evaluations were made by spot urine solute/creatinine measurements.

Two mechanisms explain why metabolic factors cause stone formation. First, increased renal excretion of solutes such as calcium, oxalate, uric acid, and cystine or increased urinary concentrations due to low urine volume. This leads to supersaturation and precipitation of the solute, resulting in the formation of crystals that can aggregate into a stone. Second, natural inhibitors of urinary stone formation are scarce, such as citrate, magnesium, and pyrophosphate. Low levels of these inhibitors, especially hypocitraturia, are

associated with kidney stones in adults and children. In two case series of children with kidney stones, approximately 90 percent of the patients had at least one metabolic risk factor (7,20). In some studies from our country, Alpay et al. (18) in 87% of patients, Melek et al. (13) in 69.7%, and Taşdemir et al. (14) in 34.8% detected a metabolic cause. Our study found one or more metabolic disorders in 58.2% of the patients.

The most common metabolic abnormality associated with pediatric stone disease is hypercalciuria (21). In most of the studies conducted in our country, hypercalciuria was found to be the most common cause, while in some studies, hypocitraturia was reported more frequently (13,14,18,22). In our study, a single metabolic disorder was detected in 53.3% of the patients, and nearly half of them (20.5%) were hypercalciuria. The rise in excretion of calcium in the urine can be attributed to three mechanisms: increased intestinal absorption (absorptive hypercalciuria), renal tubular calcium reabsorption defect (renal hypercalciuria), and increased bone resorption (resorptive hypercalciuria) (23). Inadequate fluid intake, immobilization, medications such as diuretics and glucocorticoids, excessive vitamin D, and high-salt diets are environmental factors that can cause hypercalciuria.

Other metabolic abnormalities detected in our study were hypocitraturia, hyperoxaluria, hyperuricosuria, cystinuria, and hypomagnesuria, respectively. Citrate is an inhibitor of calcium oxalate and calcium phosphate crystallization. Hypocitraturia is more common in adult patients with idiopathic kidney stones than in children. Although hypocitraturia is mostly idiopathic, a diet rich in animal proteins and low in potassium and plant foods contributes to a decrease in citrate excretion (24).

In our study, hypocitraturia was the second most common cause of stones and was present in 17.2% of the patients. This rate was similar to that of some child studies in our country (19,25). Furthermore, hypocitraturia (34.1%) was the predominant metabolic abnormality observed in our patients whose stones reduced in size or disappeared.

Oxalate, the end product of glyoxylate and ascorbic acid metabolism, is excreted through the kidneys. In our study, hyperoxaluria was the third most frequently detected metabolic disorder. None of our patients had primary hyperoxaluria, which is a genetic-metabolic disease. Idiopathic hyperuricosuria is thought to result from a defect in renal tubular uric acid excretion, and hyperuricosuria is

detected in 2 to 8 percent of children with urinary stones. Although Elmaci et al. (26) and Kara et al. (19) have reported that hyperuricosuria is the most common metabolic disorder in children in our country, the frequency of hyperuricosuria in our study was found to be in line with the frequency reported in the literature. More than one metabolic disorder may occur together in some children with urinary system stones (14,18). In 4.9% of our patients, we have identified more than one metabolic disorder.

As a result, in this retrospective study conducted in children with urinary system stones, there was no gender difference, family history was common, the most common presenting symptom was abdominal/flank pain or restlessness, stones were generally located in the upper urinary system, microlithiasis was found at a considerable rate, anatomical problems could be detected, the most common presenting symptom was abdominal/flank pain or restlessness. It has been determined that the important predisposing factor is a metabolic disorder and that most of the stones shrink and disappear completely with medical treatment.

CONCLUSIONS

Identifying the cause of urinary tract stones and, in particular, detecting underlying metabolic disorders is a major contribution to preventing new stone formation, as well as planning successful diet and pharmacological therapy. We believe it is possible to reduce or eliminate urinary tract stones and prevent their recurrence with early diagnosis of urinary tract stones in children, identification of metabolic disorders, and effective treatment.

Conflicts of Interest: None of the contributing authors have any conflict of interest, including specific financial interests or relationships and affiliations relevant to the subject matter or materials discussed in the manuscript.

Funding: None.

Ethical Approval: Memorial Bahçelievler Hospital Ethics Committee, Approval Number: 114, Date: 2024-01-25.

Author Contributions: Conception and dizayn; MÇ, AMÇ, MSS, Data acquisition; MÇ, AMÇ, MSS, Data analysis and interpretation; MÇ, MSS, Drafting the manuscript; MÇ, AMÇ, MSS, Critical revision of the manuscript for the content; MSS, Statistical analysis; MÇ, AMÇ, Supervision; MÇ, MSS.

REFERENCES

1. Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, Lieske JC, Rule AD. Temporal trends in incidence of kidney stones among children: a 25-year population based study. *J Urol* 2012;188:247-252. <https://doi.org/10.1016/j.juro.2012.03.021>
2. Pearle MS, Antonelli JA, Lotan Y. Urinary Lithiasis: Etiology, Epidemiology, and Pathogenesis. In: Wein AJ (ed) CampbellWalsh Urology, 17th edn. Philadelphia: Elsevier; 2016. p.1170-1199. <https://doi.org/10.1016/j.eururo.2014.06.036>
3. Çivilbal M, Selçuk Duru N, Eevli M. Çocuklarda Üriner Sistem Taşları. *Med Bull Haseki* 2016;54:1-6. <https://doi.org/10.4274/haseki.2727>
4. Coward RJ, Peters CJ, Duffy PG, et al. Epidemiology of paediatric renal stone disease in the UK. *Arch Dis Child* 2003; 88:962-965. <https://doi.org/10.1136/adc.88.11.962>
5. Perrone HC, dos Santos DR, Santos MV, et al. Urolithiasis in childhood: metabolic evaluation. *Pediatr Nephrol* 1992; 6:54-56. <https://doi.org/10.1007/BF00856834>
6. Celiksoy MH, Yilmaz A, Aydogan G, Kiyak A, Topal E, Sander S. Metabolic disorders in Turkish children with urolithiasis. *Urology* 2015;85:909-913. <https://doi.org/10.1016/j.urology.2014.12.032>
7. Spivacow FR, Del Valle EE, Boailchuk JA, Díaz GS, Ugarte VR, Álvarez ZA. Metabolic risk factors in children with kidney stone disease: an update. *Pediatr Nephrol* 2020;35:2107-2112. <https://doi.org/10.1007/s00467-020-04660-x>
8. Drach GW. Metabolic evaluation of pediatric patients with stones. *Urol Clin North Am* 1995;22:95-100. PMID: 7855963
9. Clayton DB, Pope JC. The increasing pediatric stone disease problem. *Ther Adv Urol* 2011;3:3-12. <https://doi.org/10.1177/1756287211400491>
10. Ece A, Ozdemir E, Gurkan F, Dokucu AI, Akdeniz O. Characteristics of pediatric urolithiasis in south-east Anatolia. *Int J Urol* 2000;7:330-334. <https://doi.org/10.1046/j.1442-2042.2000.00207.x>
11. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. *J Am Soc Nephrol* 1997;8:1568-1573. <https://doi.org/10.1681/ASN.V8101568>

12. Öner A, Demircin G, Ipekçioğlu H, Bulbul M, Ecin N. Etiological and clinical patterns of urolithiasis in Turkish children. *Eur Urol* 1997;31:453-458. <https://doi.org/10.1159/000474506>
13. Melek E, Gülleroğlu KS, Bayrakçı US, Aygün C, Baskın E. Üriner sistem taşı olan çocuk hastaların klinik ve metabolik özellikleri. *Türkiye Çocuk Hast Derg*. 2016;1:40-45. <https://doi.org/10.12956/tjpd.2015.168>
14. Taşdemir M. Üriner sistem taşı olan çocuklarda metabolik bozukluklar ve cinsiyetin etkisi. *Şişli Etfal Hastanesi Tıp Bülteni* 2017;51:218-224. <https://doi.org/10.5350/SEMB.2017041701410>
15. VanDervoort K, Wiesen J, Frank R, et al. Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. *J Urol* 2007;177:2300-2305. <https://doi.org/10.1016/j.juro.2007.02.002>
16. Kalorin CM, Zabinski A, Okpareke I, White M, Kogan BA. Pediatric urinary stone disease--does age matter? *J Urol* 2009;181:2267-2271. <https://doi.org/10.1016/j.juro.2009.01.050>
17. Cassim R, Van Walraven C, Lavallée LT, et al. Systematic radiologic detection of kidney stones in Canadian children: a new era of asymptomatic stones? *J Pediatr Urol* 2019;15:467.e1-467.e7. <https://doi.org/10.1016/j.jpuro.2019.05.012>
18. Alpay H, Ozen A, Gokce I, Biyikli N. Clinical and metabolic features of urolithiasis and microlithiasis in children. *Pediatr Nephrol* 2009;24:2203-229. <https://doi.org/10.1007/s00467-009-1231-9>
19. Kara A, Gürgöze MK, Gözütok AU. Üriner Sistem Taş Hastalığı Olan Çocukların Metabolik Değerlendirmesi. *Fırat Tıp Dergisi* 2018;23:142-145.
20. Penido MG, Srivastava T, Alon US. Pediatric primary urolithiasis: 12-year experience at a Midwestern Children's Hospital. *J Urol* 2013;189:1493-1497. <https://doi.org/10.1016/j.juro.2012.11.107>
21. DeFoor W, Minevich E, Jackson E, et al. Urinary metabolic evaluations in solitary and recurrent stone forming children. *J Urol* 2008;179:2369-2372. <https://doi.org/10.1016/j.juro.2008.01.151>
22. Ertan P, Tekin G, Oger N, Alkan S, Horasan GD. Metabolic and demographic characteristics of children with urolithiasis in Western Turkey. *Urol Res* 2011;39:105-110. <https://doi.org/10.1007/s00240-010-0306-1>
23. Aladjem M, Barr J, Lahat E, Bistrizter T. Renal and absorptive hypercalciuria: a metabolic disturbance with varying and interchanging modes of expression. *Pediatrics* 1996;97:216-219.
24. Hess B, Michel R, Takkinen R, Ackermann D, Jaeger P. Risk factors for low urinary citrate in calcium nephrolithiasis: low vegetable fibre intake and low urine volume to be added to the list. *Nephrol Dial Transplant* 1994;9:642-649. <https://doi.org/10.1093/ndt/9.6.642>
25. Gürgöze MK, Sarı MY. Results of medical treatment and metabolic risk factors in children with urolithiasis. *Pediatr Nephrol* 2011;26:933-937. <https://doi.org/10.1007/s00467-011-1803-3>
26. Elmacı AM, Ece A, Akın F. Clinical characteristics and metabolic abnormalities in preschool-age children with urolithiasis in South-East Anatolia. *J Pediatr Urol* 2014;10:495-499. <https://doi.org/10.1016/j.jpuro.2013.11.004>

Inter-Observer Reliability and Reproducibility of CROES, Guy's and STONE Nephrolithometry Scoring Systems for Predicting Percutaneous Nephrolithotomy Outcomes

Ali Ayrancı¹, Ufuk Çağlar¹, Hakan Çakır², Arda Meriç¹, Ufuk Can Aksu¹, Faruk Özgör¹, Ömer Sarılar¹

¹Department of Urology, Haseki Training and Research Hospital, Istanbul, Türkiye

²Department of Urology, Fulya Acibadem Hospital, Istanbul, Türkiye

Submitted: 2024-03-28

Accepted: 2024-06-28

Correspondence

Ali Ayrancı, MD

Address: Haseki Training and Research Hospital, Millet Street, Istanbul, Türkiye

E-mail: draliayranci@yahoo.com

ORCID

A.A. [0000-0003-3747-0869](https://orcid.org/0000-0003-3747-0869)

U.Ç. [0000-0002-4832-9396](https://orcid.org/0000-0002-4832-9396)

H.Ç. [0009-0003-7341-8360](https://orcid.org/0009-0003-7341-8360)

A.M. [0000-0002-2611-2815](https://orcid.org/0000-0002-2611-2815)

U.C.A. [0009-0003-4326-8197](https://orcid.org/0009-0003-4326-8197)

F.Ö. [0000-0001-8712-7458](https://orcid.org/0000-0001-8712-7458)

Ö.S. [0000-0002-1273-1084](https://orcid.org/0000-0002-1273-1084)

Abstract

Objective: To assess inter-observer reliability and reproducibility of CROES, Guy's and S.T.O.N.E. nephrolithometry scoring systems (NSS).

Material and Methods: A total of 128 patients who underwent percutaneous nephrolithotomy (PNL) between January 2019 and January 2021 were included in the study. Calculation of the CROES, S.T.O.N.E., and Guy's NSSs was made by three independent urologists with different academic levels. These were; a very experienced (>500 PCNL cases) endourologist (Rater 1), a urologist who had just finished (>100 PCNL cases) their urology education (Rater 2) and a 3rd year urology resident who had never performed a PCNL operation (Rater 3). All were blinded to the procedure outcomes.

Results: An excellent correlation was found between three raters for Guy and S.T.O.N.E. scoring systems (kappa value 0.810-0.962). However, for the CROES score there is an excellent correlation between Rater 1 and Rater 2, but there were good correlations between Rater 1 vs Rater 3 and Rater 2 vs Rater 3 (kappa values 0.910 and 0.698-0.721 respectively). The highest correlation was between Rater 1 and Rater 2 for Guy score (kappa value 0.962) (Table 3). All intra-class correlations were statistically significant (p<0.001). The highest intra-class correlations were seen for the S.T.O.N.E. score (ICC: 0.980).

Conclusion: The present study revealed that all three NSS frequently used in current urology practice have reproducible and reliable results. Additionally, we believe that the application of CROES NSS by more experienced clinicians will be effective in obtaining clearer results.

Keywords: nomogram, scoring systems, percutaneous nephrolithotomy, surgery of renal stones

INTRODUCTION

Percutaneous nephrolithotomy (PNL) is an accepted treatment method for kidney stones greater than 2 cm (1). Success and complications may be affected by many factors including surgeon experience, renal anatomy, and complexity

of renal stones. Outcomes of PNL have been reported to have wide ranges in the literature. Therefore, several nephrolithometry scoring systems (NSS) were developed for extensive patient counselling, surgical planning, and assessment of PNL results. Additionally, NSSs are used to

Cite: Ayrancı A, Çağlar U, Çakır H, Meriç A, Aksu UC, Özgör F, Sarılar O. Inter-Observer Reliability and Reproducibility of CROES, Guy's and STONE Nephrolithometry Scoring Systems for Predicting Percutaneous Nephrolithotomy Outcomes. *New J Urol.* 2024;19(2):85-89. <https://doi.org/10.33719/nju1388671>

quantify the complexity of the stone in scientific papers (2).

Recently, three NSSs including the S.T.O.N.E. NSS, the Clinical Research Office of the Endourological Society (CROES) NSS and Guy's NSS are widely used in urology practice (3, 4, 5). After development of an NSS, its predictive accuracy is evaluated by internal and external validation. Although predictive accuracy seems to be the most important factor, simplicity, reproducibility, and achieving the same results with different clinicians are other important properties for an ideal nomogram. Optimally, scores achieved should be similar irrespective of the educational degree and level of expertise of the observer.

Although previous reports validated NSSs in predicting PNL outcomes, none of these studies compared the reproducibility and reliability of the 3 NSSs. In the present study, we evaluated CROES, Guy's and S.T.O.N.E. NSSs for reliability and reproducibility by analysing the scores calculated by 3 raters with different experience level.

MATERIAL AND METHODS

After approval from the Haseki Training and Research Hospital Clinical Research Ethics Committee (Approval Number:280-2023), we performed a retrospective study among patients who underwent conventional PNL from January 2019 to January 2021. Patients with missing data, patients < 18 years old, and patients who did not have pre-operative non-contrast abdominal computed tomography (NCCT) were excluded from the study. Evaluation of stone size, location, and density were evaluated by NCCT. All procedures were performed in the same manner and technique of PNL was described in detail previously. Stone-free status was assessed by NCCT 1-3 months later. Patients who had fragments not larger than 4 mm were considered stone free. Postoperative complications were categorized according to Clavien-Dindo (6).

Nephrolithometry Scoring System Assessment

Calculation of NSSs was made by three urologists with different experience levels (endourologist with >500 PNL, Rater 1; urologist with >100 PNL, Rater 2 and a 3rd year urology resident who had never performed a PNL, Rater 3). All were blinded to the procedure outcomes. CROES NSS (grade 1:0–100, grade 2:101–150, grade 3:151–200, and grade 4:201–350), S.T.O.N.E. NSS (scores between 5 and 13), and Guy's SS NSS (grade 1, 2, 3, 4) were analyzed (3,4,5). Case volume of the center: 500 cases per year.

Statistical Analysis

Statistical Package of Social Sciences for Windows (SPSS) version 20 was used. The compliance of data was evaluated by the Shapiro-Wilk test. Categorical variables were compared with Fisher's exact or Chi-square test. Sample *t* test was used for continuous parameters. Correlation analyses were done using Pearson's correlation coefficient. The Kappa value <0.20 reflects slight agreement, values of 0.21-0.40 are considered fair, 0.41-0.60 moderate, 0.61-0.80 good, and 0.81-1 indicates almost perfect agreement (7). Intra-class correlation was based on a two-way random effects model with type consistency. *P* <0.05 was considered statistically significant.

RESULTS

A total of 128 patients (86 males and 42 females) were included in the study. According to Rater 1, the mean stone size was 516.5 ± 370.6 mm², the mean stone-skin distance was 90.4 ± 24.2 mm and the mean Hounsfield unit (HU) was 1013.8 ± 301.0 . The mean operation time and hospitalization time was 80.9 ± 32.7 minutes and 73.2 ± 45.3 hours respectively.

In total, 30 patients (23.4%) experienced complications. According to Clavien Dindo classification complication degree distribution was 6 patients with grade 1, 10 patients with grade 2, two patients with grade 3a and 12 patients with grade 3b. The stone-free status was achieved in 73.4% of patients (94 of 128 patients) (Table 1).

After all scoring systems were calculated by each rater, the Guy scores were 1.9 ± 0.9 , 2.0 ± 0.9 , and 2.1 ± 0.9 , S.T.O.N.E. scores were 7.9 ± 1.4 , 8.0 ± 1.4 , and 8.8 ± 1.3 , and CROES scores 202.9 ± 64.6 , 203.7 ± 60.7 , 173.1 ± 61.4 , respectively according to raters (Table 2).

An excellent correlation was found between the three raters for Guy and S.T.O.N.E. scoring systems (kappa value 0.810-0.962). However, for the CROES score there was an excellent correlation between Rater 1 and Rater 2, but there were good correlations between Rater 1 vs Rater 3 and Rater 2 vs Rater 3 (kappa value 0.910 and 0.698-0.721 respectively). The highest correlation was between Rater 1 and Rater 2 for Guy score (kappa value 0.962) (Table 3). All intra-class correlations were statistically significant (*p*<0.001). The highest intra-class correlations were seen for the S.T.O.N.E. score (ICC: 0.980) (Table 4).

Table 1. Patient information

Number of Patients		128
Gender	Female*	42(32.8%)
	Male*	86(67.2%)
Age (years)*		47.2 ± 14.6
BMI (kg/m²)*		27.4 ± 4.9
Operation side	Right*	70(54.7%)
	Left*	58(45.3%)
Stone size (mm²)*^α		516.5 ± 370.6
Stone - skin distance (mm)*^α		90.4 ± 24.2
Hounsfield Unit*^α		1013.8 ± 301.0
Operation time (minutes)*		80.9 ± 32.7
Hospitalization time (hours)*		73.2 ± 45.3
Stone free status		94 (73.4%)
Complications	Total*	30 (23.4%)
	Grade 1*	6 (4.7%)
	Grade 2*	10 (7.8%)
	Grade 3a*	2 (1.6%)
	Grade 3b*	12 (9.3%)

*: mean±standard deviation or number (%)

α: According to rater 1

BMI: Body Mass Index

Table 2. Scoring systems according to raters

	Rater 1	Rater 2	Rater 3
CROES	202.9 ± 64.6	203.7 ± 60.7	173.1 ± 61.4
Guy	1.9 ± 0.9	2.0 ± 0.9	2.1 ± 0.9
S.T.O.N.E.	7.9 ± 1.4	8.0 ± 1.4	8.8 ± 1.3

CROES: Clinical Research Office of the Endourological Society, S.T.O.N.E.: stone size, tract length, degree of obstruction, number of involved calyces and stones' density

Table 3. Kappa correlation coefficient for all raters and scoring systems

Guy Score		
	Rater 2*	Rater 3*
Rater 1*	0.962 (0.940-0.984)	0.810 (0.760-0.850)
Rater 2*		0.819 (0.775-0.863)
STONE Score		

	Rater 2*	Rater 3*
Rater 1*	0.948 (0.923-0.973)	0.911 (0.878-0.944)
Rater 2*		0.910 (0.877-0.943)
CROES Score		
	Rater 2*	Rater 3*
Rater 1*	0.910 (0.879 -0.941)	0.721 (0.671-0.771)
Rater 2*		0.698 (0.646-0.750)

*: 95% confidence

CROES: Clinical Research Office of the Endourological Society, S.T.O.N.E.: stone size, tract length, degree of obstruction, number of involved calyces and stones' density

Table 4. Intra-class correlation among all raters for scoring systems

	ICC	95% CI	p value
Guy	0.978	0.970-0.984	0.001
STONE	0.980	0.974-0.986	0.001
CROES	0.964	0.951-0.973	0.001

CI: confidence interval, ICC: Intra-class correlation

CROES: Clinical Research Office of the Endourological Society, S.T.O.N.E.: stone size, tract length, degree of obstruction, number of involved calyces and stones' density

DISCUSSION

Nomograms in surgical practice are usually used to predict complexity of disease and surgical outcomes; additionally they are used to determine the deviations from normality in internal medicine practice (8, 9, 10). The applicability and effectiveness of nomograms are frequently discussed and researched (11, 12). Researchers mostly focus on the ability of nomograms to predict outcomes; however, questioning of the compatibility and repeatability of the nomograms, and reliability between raters have not been clearly investigated (13). Nomograms can yield different results in terms of accuracy, but it is uncertain whether these differences are due to the nomograms themselves or the clinicians evaluating them. The question of who is the most suitable clinician to evaluate nomograms remains unanswered.

Three NSS are widely used in daily urology practice. In a recent meta-analysis, studies evaluating these three nomograms were examined and all three were stated to be suitable with equal power and accuracy in predicting stone-

free rates (14). However, another important situation is to compare whether these scoring systems always give the same results or not independently of the clinician applying them. In a recent study, the CROES nomogram was applied to their own patient population by 4 independent raters, and they stated that there was excellent agreement between the raters according to the nomogram scores. In the present study, an excellent correlation was determined between Guy's and S.T.O.N.E. NSSs. Experience affected the results most for the CROES NSS. When the correlation was evaluated for the CROES NSS, the results of 2 experienced raters were still perfectly compatible. However, the inexperienced clinician (rater 3) had a lower correlation score compared to both experienced raters. According to the intra-class correlation analyses, the highest correlation was seen for S.T.O.N.E. score and all three NSS achieved a statistical significance.

Analyzing the internal dynamics of these three NSS in detail revealed that there were differences in their natures. In the original article about CROES, stone burden, stone location and stone number are described with figures, but staghorn stone is not defined. The calculation of the score is done by the addition of 6 two-digit numbers marked on a scale. In addition, the size of the stone is obtained by a process that requires a calculator such as " $\text{width}_{\max} \times \text{length}_{\max} \times 0.785$ ". When "human error" is taken into account in the application of this score, it involves risks that will prevent obtaining the exact values (15). When the Guy's score is evaluated, the NSS is described with kidney illustrations and the final score is obtained by selecting one of the 4 categories. The lack of requirement for any mathematical operation makes the scoring system the simplest scoring system applied. Our third NSS of S.T.O.N.E. consists of 5 questions, and the answer to these questions comprise numbers from 1 to 4. Scores are obtained by adding these 5 single-digit numbers without the need for a calculator. In light of these explanations, the reason why the first two NSS have excellent correlation and the last one has good correlation between raters is due to the simple-complex nature of these NSSs. It is crucial to emphasize that for a nomogram to be clinically useful, its evaluations must demonstrate consistency across different observers. This consistency ensures that the outcomes are not influenced by subjective human factors, thus maintaining the reliability and validity of the tool. Our results indicate that the evaluations of all three nephrolithometry scoring systems (CROES, Guy's, and S.T.O.N.E.) exhibited high levels of agreement among raters with varying levels of experience. This high degree of similarity underscores the robustness

and reproducibility of these nomograms, reinforcing their utility in clinical practice irrespective of the evaluator's expertise.

The retrospective nature of the study inherently introduces potential biases and limits the ability to establish causality. and relatively small patient number in the study could be considered limitations. Secondly, evaluating data for 128 patients according to 3 different nomograms in a short period of time of 1 week may have caused mental fatigue in the authors and affected their evaluation abilities.

CONCLUSION

We have two recommendations. First of all, this analysis could be made with a larger clinician population to achieve better conclusions and prevent mental fatigue of each clinician participating in the study. Secondly, we aimed to provide a guide for who is eligible to analyse nomograms but we did not evaluate whether the analysis could be made fully by artificial intelligence (AI) to prevent human error completely. We often see studies about AI in the field of radiology which may be subject of further studies in urology field (16).

The present study revealed that all three NSS have reproducible and reliable outcomes in prediction of PNL outcomes. Additionally, we found that the use of CROES NSS by more experienced clinicians will be effective in obtaining more clear results.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest: None of the contributing authors have any conflict of interest, including specific financial interest and relationships and affiliations relevant to the subject matter of materials discussed in the manuscript.

Consent of Informed: The authors declare that written informed consent was obtained from the patients for publication of these reports.

Authors' Contributions: Conception and dizayn; Ayranci A, Data acquisition; Ayranci A, Cakir H, Data analysis and interpretation; Meriç A, Drafting the manuscript; Ayranci A, Cakir H, Critical revision of the manuscript for the content; Ayranci A, Ozgor F, Statistical analysis; Caglar U,

Supervision; Ozgor F, Sarilar O.

Ethics Committee: Haseki Training and Research Hospital Clinical Research Ethics Committee, Date: 01.02.2023, Protocol: 29-2023.

REFERENCES

1. Turk C, Neisius A, PEtrik A, Seitz C, Skolarikos A, Thomas K et al. EAU guidelines on urolithiasis. European Association of Urology. <https://uroweb.org/guideline/prostate-cancer/> Edn. presented at the EAU Annual Congress Amsterdam 2020. EAU Guidelines Office, Arnhem, The Netherlands. ISBN 978-94-92671-07-3.
2. Sfoungaristos S, Mykoniatis I, Isid A, et al. Interobserver Reliability and Reproducibility of the Clinical Research Office of the Endourological Society Nomogram in Predicting Percutaneous Nephrolithotomy Results. *Urology*. 2016;97:56–60. <https://doi.org/10.1016/j.urology.2016.07.014>
3. Thomas K, Smith NC, Hegarty N, et al. The Guy's stone score--grading the complexity of percutaneous nephrolithotomy procedures. *Urology*. 2011;78:277-281. <https://doi.org/10.1016/j.urology.2010.12.026>
4. Okhunov Z, Friedlander JI, George AK, et al. S.T.O.N.E. nephrolithometry: novel surgical classification system for kidney calculi. *Urology*. 2013;81:1154- 1159. <https://doi.org/10.1016/j.urology.2012.10.083>
5. Smith A, Averch TD, Shahrour K, et al. A nephrolithometric nomogram to predict treatment success of percutaneous nephrolithotomy. *J Urol*. 2013;190:149-156. <https://doi.org/10.1016/j.juro.2013.01.047>
6. Clavien dindo: Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg*. 250:187-196 <https://doi.org/10.1097/SLA.0b013e3181b13ca2>
7. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. 1977;33(1):159-174. PMID: 843571
8. Cantinotti M, Giordano R, Clemente A, et al. Strengths and Limitations of Current Adult Nomograms for the Aorta Obtained by Noninvasive Cardiovascular Imaging. *Echocardiography*. 2016;33(7):1046-1068. <https://doi.org/10.1111/echo.13232>
9. Stojadinovic MM, Prelevic RI. External validation of existing nomograms predicting lymph node metastases in cystectomized patients. *Int J Clin Oncol*. 2015;20(1):164-170. <https://doi.org/10.1007/s10147-014-0693-3>
10. Onal B, Tansu N, Demirkesen O, et al. Nomogram and scoring system for predicting stone-free status after extracorporeal shock wave lithotripsy in children with urolithiasis. *BJU Int*. 2013;111(2):344-352. <https://doi.org/10.1111/j.1464-410X.2012.11281.x>
11. Ozgor F, Tosun M, Kayali Y, Savun M, Binbay M, Tepeler A. External Validation and Evaluation of Reliability and Validity of the Triple D Score to Predict Stone-Free Status After Extracorporeal Shockwave Lithotripsy. *J Endourol*. 2017;31(2):169-173. <https://doi.org/10.1089/end2016.0721>
12. Yanaral F, Ozgor F, Savun M, Sahan M, Sarilar O, Binbay M. Comparison of CROES, S.T.O.N.E, and Guy's scoring systems for the prediction of stone-free status and complication rates following percutaneous nephrolithotomy in patients with chronic kidney disease. *Int Urol Nephrol*. 2017;49(9):1569-1575. <https://doi.org/10.1007/s11255-017-1631-x>
13. Cantinotti, M., Scalese, M., Giordano, R. et al. A statistical comparison of reproducibility in current pediatric two-dimensional echocardiographic nomograms. *Pediatr Res*. 89, 579-590 (2021). doi: 10.1038/s41390-020-0900-z.
14. Jiang K, Sun F, Zhu J, et al. Evaluation of three stone-scoring systems for predicting SFR and complications after percutaneous nephrolithotomy: a systematic review and meta-analysis. *BMC Urol*. 2019;19(1):57. <https://doi.org/10.1186/s12894-019-0488-y>
15. Sameera, V., Bindra, A., & Rath, G. P. Human errors and their prevention in healthcare. *Journal of anaesthesiology, clinical pharmacology*, 2021;37(3):328-335. https://doi.org/10.4103/joacp.JOACP_364_19
16. Wang F, Gu X, Chen S, et al. Artificial intelligence system can achieve comparable results to experts for bone age assessment of Chinese children with abnormal growth and development. *PeerJ*. 2020;8:e8854. <https://doi.org/10.7717/peerj.8854>

The Role of Hematologic Parameters in Predicting Orchiectomy for Testicular Torsion

Cengiz Çanakçı, Erdinç Dinçer, Orkunt Özkaptan, Medet Sevinç, Bilal Eryıldırım

Department of Urology, Health Sciences University, Kartal Dr. Lutfi Kırdar City Hospital, Istanbul, Türkiye

Submitted: 2024-02-20

Accepted: 2024-06-26

Correspondence

Cengiz Çanakçı, MD

Kartal Dr. Lutfi Kırdar City Hospital

D100 Güney Yanyol Cevizli 34890

Kartal / İstanbul / Türkiye

E-mail: cengizcanakci@hotmail.com

ORCID

C.Ç. [0000-0002-2654-1986](https://orcid.org/0000-0002-2654-1986)

E.D. [0000-0002-0644-8282](https://orcid.org/0000-0002-0644-8282)

O.Ö. [0000-0003-3659-1319](https://orcid.org/0000-0003-3659-1319)

M.S. [0009-0007-3484-397X](https://orcid.org/0009-0007-3484-397X)

B.E. [0000-0002-2213-3985](https://orcid.org/0000-0002-2213-3985)

Abstract

Objective: Testicular torsion is an urological emergency that requires early intervention. When torsion is diagnosed late, the possibility of organ loss increases. In this study, we investigated the role of preoperative hematological parameters in predicting orchiectomy.

Material and Methods: A total of 136 patients who had undergone surgery due to testicular torsion were included in this study. Patients are divided into two groups as orchiectomy (n=48) and testicular fixation (n=88). The groups were compared with age, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), platelet count (PLT), mean platelet volume (MPV), neutrophil count, lymphocyte count, symptoms of duration, side and the degree of torsion.

Results: The mean age was 18.2 ± 9.6 in orchiectomy group and 17.2 ± 6.1 in testicular fixation group ($p=0.569$). The symptoms of duration was statistically higher in orchiectomy group (57.4 ± 35.7 vs. 8.7 ± 7.4 ($p=0.001$)). NLR was 5.03 ± 2.93 in orchiectomy group and 6.72 ± 3.51 in testicular fixation group ($p=0.005$). MPV was found to be significantly higher in the orchiectomy group ($p=0.001$). There were no differences between the groups in terms of the PLR ($p=0.137$), PLT ($p=0.251$), neutrophil count ($p=0.309$) and lymphocyte count ($p=0.895$). In multivariate analysis, the degree of torsion and the duration of symptoms were found to be predictive for orchiectomy ($p=0.003$, $p<0.001$).

Conclusion: Many studies have reported that preoperative haematological parameters predict orchiectomy. However, no predictive factor was found in our study.

Keywords: Testicular Torsion, Orchiectomy, Hematological Parameters.

INTRODUCTION

Testicular torsion is an emergency condition characterized by the rotation of spermatic cord around itself and has incidence of 1/4000 of men under the age of 25 (1). As a result of torsion, testicular blood supply is impaired, ischemia occurs and the risk of infertility increases (2). The possibility of testicular ischemia is depends on the duration of symptoms (1). It is

diagnosed with physical examination and scrotal doppler ultrasonography. If intervention occurs within the first 6 hours after the onset of torsion, the possibility of undergone orchiectomy decreases, whereas if it continues longer than 12 hours, the orchiectomy rate increases dramatically (3,4). 31-41% of cases result in orchiectomy and it may cause severe consequences such as decreased fertility rate, hormonal

Cite; Çanakçı C, Dinçer E, Özkaptan O, Sevinç M, Eryıldırım B. The Role of Hematologic Parameters in Predicting Orchiectomy for Testicular Torsion. New J Urol. 2024;19(2):90-94. <https://doi.org/10.33719/nju1439058>

dysfunction and psychological trauma (5).

The most important parameters that affecting recovery is the onset of symptoms and depends entirely on the information given by patient. Patients are mainly at pediatric ages and the time of onset of symptoms is subjective (6). Besides that, it prolongs the process of application to clinic because the teenagers do not consent to genital area examination (7).

Some studies in the literature have indicated that haematological parameters may be useful in predicting testicular viability in the presence of testicular torsion. Neutrophil-Lymphocyte Ratio (NLR) is a simple blood test result that has proven predictive role in many disorder and has become more popular lately. It is an inflammation parameter and has previously been used to differentiate between testicular torsion and epididymitis (1,8). In this study, we aimed to investigate the results of hematological parameters in predicting the orchiectomy in testicular torsion in a large population.

MATERIAL AND METHODS

The patients' data who had undergone orchiectomy or testicular fixation due to testicular torsion between January 2013 and January 2023 were analyzed retrospectively. The patients' age, side, duration of symptoms, medical and surgical history, the degree of torsion and preoperative hematological parameters were evaluated. The patients with the history of previous scrotal surgery, diagnosed epididymitis within 1 month and neonatal torsion were excluded. Patients who were initially diagnosed preoperatively with torsion but subsequently found not to have torsion during exploration were excluded from the study. one hundred-thirty six patients who diagnosed testicular torsion via both physical examination and scrotal doppler ultrasonography were included the study. In the patients, the testicle which appeared ischemic during scrotal exploration, was detorsioned and warm physiological saline was applied and waited for 15 minutes. Orchiectomy or testicular fixation was performed according to reperfusion. A complete blood count analysis was conducted preoperatively on all patients, with the recorded values for lymphocyte count, neutrophil count, platelet count (PLT), and mean platelet volume (MPV). The NLR and platelet-to-lymphocyte ratio (PLR) were subsequently calculated.

This study was achieved accordance to Helsinki Declaration (193/2013), approved by our Institutional Review Board (2020/514/184/2), and written informed consent was obtained from all patients before the treatment.

Statistical analysis

For descriptive statistics, mean, standard deviation and frequency were used. The Kolmogorov-Smirnov test was used to test the distribution of the variables. Quantitative data were compared using independent samples t-test and Mann-Whitney U-test. Chi-Square was used to compare qualitative data. Multivariate logistic regression analysis was performed to investigate variables which might be predictive for orchiectomy. Variables included symptom duration, testicular torsion angle, NLR, PLT, PLR, MPV. SPSS 26.0 was used for statistical analyses.

RESULTS

A total of 88 patients who had undergone testicular fixation and 48 patients who had undergone orchiectomy were compared. The demographic data of the patients and perioperative parameters are given in Table 1. The mean age was 18.2 ± 9.6 for orchiectomy group and 17.2 ± 6.1 for testicular fixation group ($p=0.569$). No differences were observed in the side and previous inguinal surgery history between the groups. ($p=0.076$, $p=0.770$ respectively). Time to surgery was significantly higher in the orchiectomy group (57.5 ± 35.7 vs. 8.7 ± 7.4) ($p=0.001$). Degree of torsion is statistically higher in the orchiectomy group ($p<0.001$).

No statistically differences were observed between the groups with regard to the PLT ($p=0.251$), neutrophil count ($p=0.309$) and lymphocyte count ($p=0.895$) (Table-2). PLR value was similar in both groups (149.8 ± 60.6 vs. 178.4 ± 105.4 respectively) ($p=0.137$). NLR was 5.03 ± 2.93 in orchiectomy group and 6.72 ± 3.51 in testicular fixation group. It was found to be significantly higher in testicular fixation group ($p=0.005$). MPV was found to be significantly higher in orchiectomy group than testicular fixation group ($p=0.001$) (8.81 ± 1.1 , 8.19 ± 0.94 , respectively). In multivariate analysis, while the degree of torsion and the duration of symptoms were found to be predictive for orchiectomy preoperatively; MPV and NLR didn't have predictive roles for orchiectomy (Table-3).

Table 1. Patient characteristics and peroperative data

	Orchiectomy mean±Sd / min-max	Orchiopexy mean±Sd / min-max	p value
Age	18.2 ± 9.6 / 4-34	17.2 ± 6.1 / 3-36	0.569
Laterality: Right (n/%)	25 (52)	32 (36)	0.076
Left (n/%)	23 (48)	56 (64)	
Symptom duration (h)	57.5 ± 35.7 / 3-160	8.7 ± 7.4 / 2-48	0.001
Previous inguinal surgery (n/%)	8 (16)	13 (14)	0.770
Testicular torsion angle (n/%)			<0.001
0-180	4 (8)	38 ((43)	
-360	21 (44)	37 (42)	
-540	11 (23)	9 (10)	
-720	9 (19)	4 (5)	
-1080	3 (6)	0	

Table 2. Hematologic parameters of the study groups

	Orchiectomy mean±Sd / min-max	Orchiopexy mean±Sd / min-max	p value
Lymphocyte (10 ³ /μL)	1.99 ± 0.73 / 6.8-19.4	1.97 ± 1.12 / 5.3-29.7	0.895
Neutrophil (10 ³ /μL)	8.8 ± 2.9 / 3.5-16	9.5 ± 3.6 / 2-19.3	0.309
PLT (10 ³ /μL)	266.0 ± 52.2 / 165-367	284.4 ± 87.7 / 140-550	0.251
NLR	5.03 ± 2.93 / 1,2-13	6.72 ± 3.51 / 0.8-16.2	0.005
PLR	149.8 ± 60.6 / 69,7-327	178.4 ± 105.4 / 46.9-507.7	0.137
MPV(μm ³)	8.81± 1.1 / 6.9-11.2	8,19± 0,94 / 6.5-10.9	0.001

PLT:platelet count; NLR:neutrophil to lymphocyte ratio; PLR:platelet to lymphocyte ratio; MPV:mean platelet volume

Table 3. Multivariate analysis results

	Odds ratio	%95 CI	P value
Symptom duration	0.833	0.757-0.917	<0.001
Testicular torsion angle	0.199	0.070-0.568	0.003
MPV	0,577	0.169-1,968	0,380
NLR	1.025	0.601-1.749	0.959
PLR	0.996	0.974-1.019	0.767
PLT	0,997	0.980-1.015	0.764

PLT:platelet count; NLR:neutrophil to lymphocyte ratio; PLR:platelet to lymphocyte ratio; MPV:mean platelet volume

DISCUSSION

In this study, it was investigated whether hematological parameters had a role in predicting orchiectomy in patients admitted due to testicular torsion.

Complete Blood Count (CBC) is a rapid test used routinely before the surgery. Various parameters in the CBC is used in the diagnosis and follow-up of many diseases (9). Although these parameters vary in acute or chronic cases, they can provide important information about the course of diseases. These parameters have recently been examined in testicular torsion, which is an acute inflammatory condition. Numerous studies have reported that hematological parameters can be used in the differential diagnosis of testicular torsion (2,10).

In a study that published in 2015, 75 patients diagnosed with torsion were compared with 56 healthy male patients. In this retrospective study, NLR, PLR and PLT values were higher in TT group. Besides that, NLR was found to be higher in patients with duration of symptoms more than 12 hours (2). In a study published in 2019, the data of 60 patients who had undergone surgical exploration with a diagnosis of torsion were retrospectively examined and orchiectomy was performed in 38 of these patients, testicular fixation was performed in 22. In this study, NLR ($p<0.001$), PLR ($p=0.01$) and WBC ($p=0.01$) values were found to be significantly higher in orchiectomy group but PLT was similar between the two groups ($p=0.28$). It is reported that NLR and the duration of symptoms has a predictive role (11). Chen et al. compared the results of 43 patients who had underwent orchiectomy, 124 patients who underwent orchiopexy, and 100 control patients, retrospectively. NLR and PLR values were found to be statistically higher in orchiopexy group but PLT value was found to be similar ($p=0.204$) (12). Meder et al. compared orchiopexy ($n=61$), orchiectomy ($n=27$) and the control groups ($n=56$). NLR was found to be statistically lower in control groups but there was no difference between orchiectomy and orchiopexy groups (13). In our study, NLR was found to be statistically higher in orchiectomy group. However, degree of torsion and symptom duration were found to be predictive, while NLR was not found to be predictive in multivariate analysis.

MPV is an indicator of platelet activation. Studies shown that MPV can be used in the diagnostic process of various inflammatory and vascular disorders. In a study, Çiçek et al. compared TT and healthy control group. MPV was found to be higher in TT group (8.3 ± 1.2 vs. 7.1 ± 0.8 , $p<0,001$) (2).

In another study which they compared the hematological parameters of 19 patients with testicular torsion, MPV found to have predictive role of testicular viability in patients with symptoms lasting less than 6 hours (14). In a retrospective study, He et al. compared orchiopexy ($n=54$) and orchiectomy ($n=58$) patients and it is found that MPV value was significantly higher in orchiectomy group. MPV was reported to be a predictive parameter in predicting orchiectomy in TT (10). In a study reported by Güneş et al, testicular torsion patients and healthy patients as control group were compared and no significant difference was found between the groups in terms of MPV (2). In another study, patients who had undergone orchiectomy and orchiopexy were compared and no difference was found between the groups in terms of MPV (12). In the present study, MPV value was found to be higher in orchiectomy group. However, it was not found to be predictive for orchiectomy in multivariate analysis. When all these findings are evaluated, the role of MPV in diagnosing torsion and predicting orchiectomy is still controversial.

The most important predictive parameter for testicular viability in testicular torsion is duration of symptoms. In some studies, it was found that the degree of testicular rotation was also predictive of testicular viability (10,12). Similarly, in our study, symptom duration and degree of testicular rotation were significantly higher in the orchiectomy group. In the regression analysis, it was found to be a predictive factor for orchiectomy.

We have two limitations in this study. First, the nature of study is retrospective. Torsion is an emergency disease that requires urgent intervention, so the patients were examined by different surgeons and scrotal doppler ultrasound was performed by different radiologists. Secondly, other inflammatory parameters such as sedimentation and CRP could not be evaluated for some patients and could not be included in this study.

CONCLUSIONS

CBC is a cheap, rapid simple blood test. Hematological parameters may be an independent variable for diagnosing testicular torsion and predicting testicular ischemia. However, the definitive diagnosis is still performed with scrotal exploration and the experience of the surgeon. Prospective studies with large population are essential to reaching certain conclusions.

Conflict of interest: The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Funding / support: The authors report no involvement in the research by the sponsor that could have influenced the outcome of this work.

Ethics Committee: Ministry of Health Kartal Dr Lütfi Kırdar City Hospital Clinical Research Ethics Committee, Date: 26.08.2020, Decision No: 220/514/184/2.

REFERENCES

1. Zhu J, Song Y, Chen G, et al. Predictive value of haematologic parameters in diagnosis of testicular torsion: Evidence from a systematic review and meta-analysis. *Andrologia*2020;52(2):e13490. <https://doi.org/10.1111/and.13490>.
2. Güneş M, Umul M, Altok M, et al. Predictive role of hematologic parameters in testicular torsion. *Korean Journal of Urology*2015;56:324-329. <https://doi.org/10.4111/kju.2015.56.4.324>.
3. Boettcher M, Bergholz R, Krebs TF, Wenke K, Aronson DC. Clinical predictors of testicular torsion in children. *Urology*2012;79:670-4. <https://doi.org/10.1016/j.urology.2011.10.041>.
4. Bowlin PR, Gatti JM, Murphy JP. Pediatric testicular torsion. *SurgClinNorthAm*2017;97:161-72. <https://doi.org/10.1016/j.suc.2016.08.012>.
5. Bodiwala D, Summerton DJ, Terry TR. Testicular prostheses: development and modern usage. *AnnRCollSurgEngl*2007;89:349-53. <https://doi.org/10.1308/003588407X183463>.
6. Rampaul MS, Hosking SW. Testicular torsion: most delay occurs outside hospital. *Ann R Coll Surg Engl* 1998;80:169-72.
7. Nasrallah P, Nair G, Congeni J, Bennett CL, McMahon D. Testicular health awareness in pubertal males. *J Urol* 2000;164:1115-7. <https://doi.org/10.1097/00005392-200009020-00049>.
8. Bitkin A, Aydın M, Özgür BC, et al. Can haematologic parameters be used for differential diagnosis of testicular torsion and epididymitis? *Andrologia*2018;50(1). <https://doi.org/10.1111/and.12819>.
9. Cicek T, Togan T, Akbaba K, Narci H, Aygun C. The value of serum mean platelet volume in testicular torsion *J Int Med Res.*2015;43(3):452-9. <https://doi.org/10.1177/0300060514558898>.
10. He M, Zhang W, Sun N. Can haematologic parameters be used to predict testicular viability in testicular torsion? *Andrologia.*2019;51:e13357. <https://doi.org/10.1111/and.13357>.
11. Jang JB, Ko YH, Choi JY, et al. Neutrophil-Lymphocyte Ratio Predicts Organ Salvage in Testicular Torsion with Marginal Diagnostic Delay. *World J Mens Health*2019;37:99-104. <https://doi.org/10.5534/wjmh.180049>.
12. Chen P, Huang W, Liu L, et al. Predictive value of hematological parameters in testicular salvage: A 12-year retrospective review *Front. Pediatr.*2022;10:989112. <https://doi.org/10.3389/fped.2022.989112>
13. Merder E, Bozkurt M, Ariman A, et al. Comprehensive examination of haematological parameters of patients operated due to testicular torsion *Andrologia*2020;52:e13674. <https://doi.org/10.1111/and.13674>.
14. Peretti M, Zampieri N, Bertozzi M, et al. Mean platelet volume and testicular torsion: new findings. *Urol J.*2019;16:83-5. <https://doi.org/10.22037/uj.v0i0.4042>

Zinner Syndrome Versus Herlyn-Werner-Wunderlich Syndrome; Rare Congenital Genitourinary Malformations and Literature Review

Saim Türkoğlu¹, Cemil Göya¹, Murat Demir²

¹Department of Radiology, Medical Faculty, Yuzuncu Yıl University, Van, Türkiye

²Department of Urology, Medical Faculty, Yuzuncu Yıl University, Van, Türkiye

Submitted: 2024-01-17

Accepted: 2024-04-30

Correspondence

Saim Türkoğlu, MD

Department of Radiology Faculty
of Medicine Yuzuncu yıl University
65100 Van, Türkiye

E-mail: mdsaimturkoglu@gmail.com

ORCID

S.T. [0000-0001-8247-2009](https://orcid.org/0000-0001-8247-2009)

C.G. [0000-0003-4792-8722](https://orcid.org/0000-0003-4792-8722)

M.D. [0000-0001-5029-8800](https://orcid.org/0000-0001-5029-8800)

Abstract

Zinner Syndrome (ZS) and Herlyn-Werner-Wunderlich Syndrome (HWWS) are congenital genitourinary anomalies accompanied by ipsilateral renal agenesis. These syndromes, which can cause symptoms such as infertility, pelvic pain, and bladder irritation, can be diagnosed by digital rectal examination, transrectal and abdominal ultrasonography (US), Computer Tomography (CT) and more ideally Magnetic resonance imaging (MRI). Similar physiopathological processes are observed in both syndromes and urogenital malformations accompany renal agenesis. We aimed to discuss the three cases of ZS in men and two HWWS cases in women, which are rarely observed in the literature.

Keywords: Zinner syndrome, Herlyn-Werner-Wunderlich syndrome, Seminal vesicle cysts, renal agenesis, mullerian duct anomaly, blind hemivagina, uterus didelphis

INTRODUCTION

Zinner syndrome (ZS) is an upper urinary tract malformation first described in 1914. It is characterized by unilateral renal agenesis, ipsilateral seminal vesicle occlusion and ipsilateral ejaculatory duct obstruction (1). Herlyn-Werner-Wunderlich syndrome (HWWS) is a rare variant of mullerian canal anomalies, occurring with blind hemivagina, uterine didelphis and unilateral renal agenesis triad (2).

A developing fetus is constantly under hormonal regulation. In the first phase of development, both XX and XY channels are indistinguishable. In the next stage, depending on

whether there are testosterone and Mullerian inhibitory factor, it differs as Wolfian duct or Mullerian duct

Similar physiopathological processes are observed in both syndromes and urogenital malformations accompany renal agenesis. We aimed to discuss the three cases of ZS in men and two HWWS cases in women, which are rarely observed in the literature. Although there is no definitive information about the etiology and pathogenesis of HWWS, it is associated with anomalies formed by the paramesonephric (Müller) and mesonephric (Wolff) ducts (3).

Cite; Türkoğlu S, Göya C, Demir M. Zinner Syndrome Versus Herlyn-Werner-Wunderlich Syndrome; Rare Congenital Genitourinary Malformations and Literature Review. New J Urol. 2024;19(2):95-102. doi: <https://doi.org/10.33719/nju1421307>

HWWS is a developmental anomaly that is accompanied by ipsilateral hemivagina obstruction and renal agenesis and is not a genetic disorder. Diagnosis can be made through non-invasive procedures such as physical examination methods and radiological examination. Most patients with HWW syndrome need to be treated surgically. The treatment plan should be made according to the affected anatomical disorder of each patient. Therefore, a detailed and comprehensive evaluation should be made before surgery.

Case- 1. The first case was a 28-year-old male patient who was admitted to the urology outpatient clinic with infertility. After physical examination and medical history, spermiogram was performed with suspicion of testicular dysfunction. Ultrasonography (US) examination was performed due to detection of azoospermia in spermiograms performed at two different times. Furthermore, the semen volume was 0.8 cc, and the pH was 7.2 in both tests. A cystic lesion was detected in the right seminal vesicle, but it could not be detected in the right kidney (agenesis). No significant abnormality was detected in the hormone tests performed.

Computed tomography (CT) revealed right renal agenesis (Fig. 1.a.b). The testicular vein calibration draining into the left renal vein was slightly thin and increased vascularity due to pelvic congestion on the left side of the pelvic region were observed (Fig. 1.c). There was also cystic tubular dilatation at the seminal vesicle level (Fig. 1.d). In MRI examination; at the seminal vesicle localization, a cystic tubular hyperintense appearance was observed, and the tubular cystic structure on the right was seen extending towards the superior. There was a cystic nodular structure in the central of prostate that caused obstruction at the ductus ejaculatorius level (Fig. 2). In addition, these cystic structures were found to be complicated by hemorrhage in T1 Weight images (Fig. 3).

Case- 2. In the routine US examination performed in a 36-year-old male patient who was followed up for Acute myeloid leukemia(AML), cystic dilated tubular structures with a maximum diameter of 30 mm were observed in the seminal vesicle localization. Further radiological examinations were performed after the patient described that he had anejaculation and had recurrent pelvic pains. In contrast-enhanced CT examination; right renal agenesis was observed and a cystic lobular lesion was detected at the level of the seminal vesicle (Fig. 4.a.b).

Case-3. In another case, dilated seminal vesicles and renal agenesis were observed in MRI examinations performed at the outpatient clinic where he admitted with similar complaints. MRI examination shows dilated seminal vesicles on coronal fat-suppressed T2 and T2-weighted images (Fig. 5.a.b.c).




Fig. 1. In CT examination; Right kidney agenesis is observed (a-b). In the left side of the pelvic region, there is an increase in pelvic vascularity (c) and an expansion in the cystic tubular structure at the level of the seminal vesicle (d).




Fig. 2. In the seminal vesicle lobe, T2 Weight images show a cystic tubular hyperintense appearance (a) and the tubular cystic structure extends towards the superior on the right (b). In the prostate central section, a cystic nodular structure that causes obstruction at the level of ductus ejaculatorius is observed (c-d).




Fig. 3. These cystic structures are observed to be complicated by hemorrhage in T1 Weight image (a) and fat-sat (b) images.




Fig. 4. In the CT examination of 36 y.o male patients; On the right, renal agenesis was observed(a) and a cystic lobular lesion was observed at the level of the seminal vesicle (b).

Case-4. 14 years-old female patient admitted with recurrent abdominal pain and irregular menstrual complaint. Imperforate hymen was detected on physical examination. Thereupon, pelvic US and MRI were examined for further examination.

In ultrasonography examination; the right kidney was not observed in place (right renal agenesis) and endometrial cavity filled with a large hemorrhagic collection extending into the cervix was observed in the pelvic area.

In MRI examination; endometrial cavity showing two separate endometrial bands surrounded by separate muscle layers(uterine didelphys) and the right of this, obstructed blind hemivagina was detected was observed in coronal T2-weighted image (Fig. 6.a). In T2-weighted sagittal images; It




Fig. 5. On T2-weighted fat-sat coronal (a) and axial (b) images; Tubular enlargement was detected in the cystic structure starting from the bilateral prostate central to the lateral and extending from the bladder inferior to the right.




Fig. 6. On MRI coronal T2-weighted image (a), an endometrial cavity showing two separate endometrial bands (uterine didelphys) surrounded by separate muscle layers was observed. And to the right of this, there is an obstructed blind hemivagina. Sagittal T2-weighted image (b) showing dilation of cervical canal with abrupt termination at vaginal fornix, resulting in obstructed hemivagina. Endometrial cavity was dilated and contained hemorrhagic collection. Axial T2-weighted image (c) showing two separate uterine horns and distention of endometrial cavity.




Fig. 7. In T2-weighted coronal MRI; Two separate endometrial cavities (a), enlargement of the cervical canal (arrow) with sudden termination of the vaginal fornix in the sagittal image (arrow), hemorrhagic collection in the endometrial cavity with obstructed hemivagina (b). In the axial fat-sat image; hematosalpinx image is observed in the left tuba (long arrow) (c).

resulted in obstructed hemivagina, which showed the cervical canal dilation with a sudden termination in the vaginal fornix. The endometrial cavity was dilated and contained a hemorrhagic collection. (Fig. 6.b). In T2-weighted axial images; Distention of two separate uterine horns and right endometrial cavities was detected (Fig. 6.c). The findings were consistent with Herlyn-Werner-Wunderlich syndrome.

Case-5. 19 years-old female patient with previously diagnosed renal agenesis admitted with irregular and painful menstruation, infertility, recurrent cyclic abdominal pain and mass complaints in the pelvic region. On physical examination; there was a palpable, well-defined soft abdominal mass extending towards the superior in the pelvic area. On gynecological examination, imperforated hymen and very enlarged, bulging uterus-cervix were detected. In the MRI examination; there was two separate endometrial cavities, widening of the cervical canal with sudden termination in the vaginal fornix, hemorrhagic collection in the endometrial cavity with obstructed hemivagina on coronal T2 (Fig. 7.a), sagittal (Fig. 7.b) and axial T1 weighted images (Fig. 7.c). There was also a hematosalpinx image in the left tuba. Radiological and clinical findings confirmed the diagnosis of Herlyn-Werner-Wunderlich syndrome.

DISCUSSION

Zinner syndrome is a Wolffian duct abnormality known with unilateral renal agenesis, ipsilateral seminal vesicle cyst and ejaculatory duct obstruction. HWWS is a rare mesonephric duct malformation with mullerian duct anomaly characterized by uterus didelphys, clogged blind hemi-vagina and ipsilateral renal agenesis (OHVIRA) syndrome. It was first reported by Wilson in 1925 (4).

Congenital anomalies of kidney and urinary tract are birth defects that affecting approximately 1% of live births (5). These anomalies include a wide range of malformations such as obstruction of ureteropelvic junction, kidney dysplasia, hypoplastic or ectopic and short ureters caused by deficiencies in embryonic kidney and lower urinary tract development. Although many gene sequences have been identified, the genetic causes of these malformations are still largely unknown (6). The morphogenesis of the urogenital system is affected by the nephric duct (ND), a common structure also known as the Wolffian duct (7). It is said by the authors that 1-2% of the cause of infertility in men has ND defects (8). Malformations that show a common etiology between the development of the urinary and genital system in the

kidneys of patients with hymen imperforation of newborn girls are observed.

Zinner syndrome is based on the common origin of ureter buds and seminal vesicles from the Wolffian duct, associated with upper urinary tract abnormalities and seminal vesicle malformation (9). This syndrome occurs after an inadequate movement in the first trimester of embryogenesis. The ureteral bud originates from the dorsal aspect of the distal mesonephric canal and extends dorsocranially to meet and stimulate the transformation of the metanephric blastema to form the adult kidney. The mesonephric duct is divided into epididymis, paradiidim, vas deferens, ejaculatory duct, seminal vesicle and hemitrigon under the influence of testosterone and anti-muller hormone (10). Alternatively, there will be abnormal ureteral budding, which leads to ipsilateral kidney agenesis or dysplasia and atresia of the ejaculatory duct and, consequently, to occlusion and cystic dilatation of the mesonephric duct (11).

HWWS is an anomaly its etiopathogenesis is not clearly explained and its true incidence is unknown. Development in embryological period is affected by genetic and environmental factors. HWWS also moves towards the paramesonephric system and methanephrosis (12).

The upper two-thirds of the uterus, fallopian tube, cervix, and vagina develop from paired paramesonephric ducts. Then, caudally, it laterally passes into the mesonephric duct, and finally, in the midline, it comes in close contact with the paramesonephric canal from the opposite side and merges to form the upper part of the uterus, cervix and vagina (13). If they do not fuse, two separate hemiuterins and hemicervices occur, resulting in mullerian anomalies associated with OHVIRA syndrome (14).

As in our cases; most patients are asymptomatic from two to four decades until high sexual and reproductive activity periods (15). The clinical picture is related to the size of the seminal vesicle cysts. Cysts smaller than 5 cm are usually diagnosed on abdominal or digital rectal examination. Symptoms occur after progressive dilatation of the seminal vesicles due to the accumulation of secretions after inadequate drainage secondary to the ejaculatory canal atresia (16). In our cases, complicated appearance was observed with hemorrhage due to these drainage disorders. Seminal vesicles are localized in the posterior of the bladder and therefore enlarged cysts may cause different symptoms

due to bladder irritation, such as dysuria, recurrent urinary tract infections, infertility painful ejaculation epididymitis and prostatitis (17-18). Larger cysts (> 12cm) can cause bladder outlet obstruction, colon obstruction, or perianal pain.

Various imaging techniques can be used in the diagnostic study of these congenital malformations. These can be listed as intravenous urography, transrectal, ultrasonography, CT examination, cystoscopy and MRI. Intravenous urography can be used to assess collecting duct system abnormalities or absence and therefore may indicate kidney agenesis. Transrectal USG can be used to determine the size and location of the associated cystic mass and its association with the seminal vesicle or prostate. It may include symptoms suggestive of bleeding or infection but is limited to small field of vision. Pelvic USG can help in the differential diagnosis, to examine whether the kidneys are in normal location, and to accurately identify the relationship of the cystic mass in the pelvic area with adjacent structures.

CT examination can accurately demonstrate pelvic anatomy and atypical kidney structures, the presence of kidney or its association with associated pathology. MR imaging may be preferred due to its relatively better contrast resolution, seminal vesicles, pelvic structures, and collector system imaging. In both of our cases, MRI was performed following CT examination.

Treatment of Zinner syndrome; Surgical resection can be performed for symptomatic seminal vesicle cysts. Also, there is infertility and there is a desire for fertility, testicular sperm extraction can be performed. There are other methods such as transrectal or transurethral interventional procedures or transurethral resection of the seminal coliculus and vas deferens. In HWWS, a therapeutic laparoscopic evaluation or vaginal septum excision can be performed to remove obstruction.

As a result; Zinner syndrome and HWWS are congenital genitourinary anomalies accompanied by ipsilateral renal agenesis. The diagnosis of these patients, which can cause symptoms such as infertility, pelvic pain, and bladder irritation, can be selected as digital rectal examination, transrectal and abdominal USG, CT examination, and the more ideal imaging method MRI. Clinical suspicion and early diagnosis can contribute to directing treatment.

Compliance with ethical standards: This article does not contain any studies with human participants or animals performed by any of the authors.

Funding: This study, being a case report, did not require any funding.

Conflict of interest: The authors declare that they have no conflict of interest.

Consent of informed: Written informed consent was obtained from the patients for publication of these reports and accompanying images.

Authors' contributions: ST, CG and MD analyzed and interpreted the patient data regarding the clinical and radiological findings of the patient. ST was major contributor in writing the manuscript. All authors read and approved the final manuscript.

REFERENCES

1. Slaoui A, Regragui S, Lasri A, Karmouni T, El Khader K, Koutani A, Ibn Attya A. Zinner's syndrome: report of two cases and review of the literature. *Basic Clin Androl.* 2016 Sep 20;26:10. <https://doi.org/10.1186/s12610-016-0037-4>.
2. Zhang H, Zheng Y, Ning G, Fu C, Bao L. Preoperative MRI presentations of Herlyn-Werner-Wunderlich syndrome. *Congenit Anom (Kyoto).* 2022 Nov;62(6):228-235. <https://doi.org/10.1111/cga.12489>.
3. Gutiérrez-Montufar OO, Zambrano-Moncayo CP, Otálora-Gallego MC, Meneses-Parra AL, Díaz-Yamal I. Herlyn-Werner-Wunderlich syndrome: case review and report of the literature. *Rev Colomb Obstet Ginecol.* 2021 Dec 30;72(4):407-422. English, Spanish. <https://doi.org/10.18597/rcog.3699>.
4. George Wilson J. A case of double uterus and vagina with unilateral hematocolpos and hematometra. *J Obstet Gynaecol Br Emp.* 1925;32: 127-8.
5. Nicolaou N, Renkema KY, Bongers EM, Giles RH, Knoers NV. Genetic, environmental, and epigenetic factors involved in CAKUT. *Nat Rev Nephrol.* 2015 Dec;11(12):720-31. <https://doi.org/10.1038/nrneph.2015.140>.

6. Heidet L, Morinière V, Henry C, De Tomasi L, Reilly ML, Humbert C, Alibeu O, Fourrage C, Bole-Feysot C, Nitschké P, Tores F, Bras M, Jeanpierre M, Pietrement C, Gaillard D, Gonzales M, Novo R, Schaefer E, Roume J, Martinovic J, Malan V, Salomon R, Saunier S, Antignac C, Jeanpierre C. Targeted Exome Sequencing Identifies PBX1 as Involved in Monogenic Congenital Anomalies of the Kidney and Urinary Tract. *J Am Soc Nephrol*. 2017 Oct;28(10):2901-2914. <https://doi.org/10.1681/ASN.2017010043>.
7. Georgas KM, Armstrong J, Keast JR, Larkins CE, McHugh KM, Southard-Smith EM, Cohn MJ, Batourina E, Dan H, Schneider K, Buehler DP, Wiese CB, Brennan J, Davies JA, Harding SD, Baldock RA, Little MH, Vezina CM, Mendelsohn C. An illustrated anatomical ontology of the developing mouse lower urogenital tract. *Development*. 2015 May 15;142(10):1893-908. <https://doi.org/10.1242/dev.117903>.
8. Hannema SE, Hughes IA. Regulation of Wolffian duct development. *Horm Res*. 2007;67(3):142-51. <https://doi.org/10.1159/000096644>.
9. Kao CC, Wu CJ, Sun GH, Yu DS, Chen HI, Chang SY, Ma CP, Cha TL. Congenital seminal vesicle cyst associated with ipsilateral renal agenesis mimicking bladder outlet obstruction: a case report and review of the literature. *Kaohsiung J Med Sci*. 2010 Jan;26(1):30-4. [https://doi.org/10.1016/S1607-551X\(10\)70005-X](https://doi.org/10.1016/S1607-551X(10)70005-X).
10. Shah S, Patel R, Sinha R, Harris M. Zinner syndrome: an unusual cause of bladder outflow obstruction. *BJR Case Rep*. 2017 Feb 15;3(2):20160094. <https://doi.org/10.1259/bjrcr.20160094>.
11. Protogerou, V., Chorti, M. & Kostakopoulos, A. Congenital dilation of seminal vesicle with agenesis of ipsilateral kidney: Symptoms and treatment. *Int Urol Nephrol* 35, 69–71 (2003). <https://doi.org/10.1023/A:1025902304134>
12. Girardi Fachin C, Aleixes Sampaio Rocha JL, Atuati Maltoni A, das Chagas Lima RL, Arias Zendim V, Agulham MA, Tsouristakis A, Dos Santos Dias AIB. Herlyn-Werner-Wunderlich syndrome: Diagnosis and treatment of an atypical case and review of literature. *Int J Surg Case Rep*. 2019;63:129-134. <https://doi.org/10.1016/j.ijscr.2019.08.035>.
13. Behr SC, Courtier JL, Qayyum A. Imaging of müllerian duct anomalies. *Radiographics*. 2012 Oct;32(6):E233-50. <https://doi.org/10.1148/rg.326125515>.
14. Sadler TW. *Langman's medical embryology*. 12th ed. Philadelphia: Lippincott Williams & Wilkins; 2012.
15. Acien P, Acien MI. The history of female genital tract malformation classifications and proposal of an updated system. *Hum Reprod Update*. 2011 Sep-Oct;17(5):693-705. <https://doi.org/10.1093/humupd/dmr021>.
16. Tan Z, Li B, Zhang L, Han P, Huang H, Taylor A, Li X. Classifying seminal vesicle cysts in the diagnosis and treatment of Zinner syndrome: A report of six cases and review of available literature. *Andrologia*. 2020 Feb;52(1):e13397. <https://doi.org/10.1111/and.13397>.
17. Rappe BJ, Meuleman EJ, Debruyne FM. Seminal vesicle cyst with ipsilateral renal agenesis. *Urol Int*. 1993;50(1):54-6. <https://doi.org/10.1159/000282451>.
18. Kenney PJ, Leeson MD. Congenital anomalies of the seminal vesicles: spectrum of computed tomographic findings. *Radiology*. 1983 Oct;149(1):247-51. <https://doi.org/10.1148/radiology.149.1.6611933>.

THE NEW JOURNAL OF UROLOGY

AUTHOR GUIDELINES

AIM

The New Journal of Urology (New J Urol) is a scientific, referred, open access publication of the Eurasian Uro-oncological Association. The society is a non-profit organization and it aims to increase the standards in the field of urology including education of the academicians, professionals and public. The New Journal of Urology aims to create or make contributions for the development of technical, scientific and social facilities and it also cooperates with any and all related institutions, organizations, foundations and societies from the national and international area for this purpose.

The journal's financial expenses are covered by the Eurasian Uro-oncological Association. The journal is published quarterly – three times a year- in February, June and October, respectively and the language of the journal are English and Turkish.

The purpose of the New Journal of Urology is to contribute to the literature by publishing urological manuscripts such as scientific articles, reviews, letters to the editor, case reports, reports of surgical techniques, surgical history, ethics, surgical education and articles of forensic medicine.

The target group of the journal consists of academicians working in the field of urology, urologists, residents of urology and all other fields of expertise and practitioners interested in urology.

Urology specialists, medical specialty fellows and other specialists who are interested in the field of urology are the journal's target audience.

SCOPE

The New Journal of Urology is currently indexed by TUBITAK ULAKBIM-TR Directory, Google Scholar, TurkMedline (National Health Sciences-Periodicals Database), Turkish Citation Index, SOBIAD Citation Index, OAJI, İdeal Online, EuroPub, J-GATE, DOAJ, EBSCO, InfoBase. The journal is integrated with ORCID and CrosReff DOI.

All published content is available for free at <https://dergipark.org.tr/en/pub/yud>.

All manuscripts submitted to the journal should be submitted through the online submission system available at <https://dergipark.org.tr/en/pub/yud>.

Instructions for authors including technical information and required forms can be found at the journal's website [https://](https://dergipark.org.tr/en/pub/yud)

dergipark.org.tr/en/pub/yud.

Editorial and publication processes of the journal are shaped in accordance with the guidelines of the international organizations such as the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE). The journal is in conformity with Principles of Transparency and Best Practice in Scholarly Publishing. (<https://doaj.org/bestpractice>).

The statements and/or opinions indicated at the articles which are published at the journal reflect the views of the author, not the opinions of the editors, editorial board and / or the publisher of the Eurasian Uro-oncological Association; Editors and publishers do not accept any responsibility for such materials.

No fee is required for submitting articles, evaluation, processing or publishing process from the authors.

Editor-in-Chief

Ali İhsan Taşçı, Department of Urology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
e-mail : alihsantasci@hotmail.com

Editor

Yavuz Onur Danacıoğlu, Department of Urology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Turkey
e-mail: dr_yonur@hotmail.com

Deputy Editor-in-Chief

Mithat Ekşi, Department of Urology, Dr.Sadi Konuk Training and Research Hospital, Istanbul, Turkey
e-mail: mithat_eksi@hotmail.com

Publishing Services

Pera Publishing Service
info@perayayincilik.com
<https://www.perayayincilik.com>

THE NEW JOURNAL OF UROLOGY

AUTHOR GUIDELINES

Information About Journal

The New Journal of Urology is an international, scientific, open access, online/published journal in accordance with independent, unbiased, and double-blinded peer-review principles, published three times a year on February, June and October. The New Journal of Urology is indexing in both international and national indexes and the publication language is English.

The New Journal of Urology has been indexed by [TUBITAK ULAKBIM-TR DİZİN](#), Google Scholar, [Index Copernicus](#), [Scilit](#), [EBSCO](#), [DOAJ](#), [EuroPub](#), [SOBIAD Citation Index](#), [OAJI](#), [J-GATE](#), [Ideal Online](#), [Turkish Citation Index](#), and [TurkMedline](#) (National Health Sciences-Periodicals Database).

The New Journal of Urology ceased printing in 2024 (ISSN: 1305-2489, eISSN: 2687-1955).

The New Journal of Urology is now only published online with the eISSN: 3023-6940.

The New Journal of Urology publishes papers on all aspects of urology and related topics. In addition to original articles, review articles, case reports and letters to the editor are also published.

The scientific board guiding the selection of the papers to be published in the journal consists of elected experts of the journal and if necessary, are selected from national and international authorities.

The authors should guarantee that the manuscripts have not been previously published and/or are under consideration for publication elsewhere. Only those data presented at scientific meetings in form of an abstract may be accepted for consideration, however, the date, name and place of the meeting in which the paper was presented should be stated. The signed statement of scientific contributions and responsibilities of all authors, and statement on the absence of conflict of interests are required. All manuscripts are reviewed by the editor and at least two experts/reviewers.

Manuscript format should be in accordance with Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (available at <https://www.icmje.org/>). The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE). The journal conforms to the Principles

of Transparency and Best Practice in Scholarly Publishing.

The New Journal of Urology does not charge for submitting articles, evaluation, processing or publishing process from the authors.

Authors' credentials and e-mail addresses are in no way used for other purposes.

The journal will allow the authors to retain publishing rights without restrictions.

All the content published in the journal can be accessed free of charge via the following link; <https://newjournalurology.com/archive>.

All submissions are screened by a similarity detection software (iThenticate by Crossref). In the event of alleged or suspected research misconduct, e.g., plagiarism, citation manipulation, and data falsification/fabrication, the Editorial Board will follow and act in accordance with COPE guidelines.

The authors should identify the individuals who accept direct responsibility for the manuscript. Each individual listed as an author should fully meet the criteria for authorship and should complete an authorship form (criteria recommended by the International Committee of Medical Journal Editors - www.icmje.org/). The corresponding author should clearly indicate the preferred citation and identify all individual authors.

When using previously published content, including figures, tables, or any other material in electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

Statements or opinions expressed in the manuscripts published in The New Journal of Urology reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility regarding the published content remains with the authors.

Journal Title:	The New Journal of Urology
Journal Abbreviation:	New J Urol
Frequency:	Tri-annual (February, June, October)
Publisher:	Ali İhsan Taşçı
Language:	English
Publication Date:	2008

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

Journal History: Continues: Yeni üroloji dergisi
eISSN: 2687-1955 (2019-2024)

Has other medium version: Yeni üroloji dergisi (printed), 1305-2489 (2008-2024)

Continued by: The New Journal of Urology
(Online), 3023-6940 (2024-)

DOI Prefix: 10.33719

Broad Subject Term(s): Oncology
Urology & Nephrology

Open Access&Licensing: OA
Creative Commons CC BY
Attribution 4.0 International

(<http://creativecommons.org/licenses/by/4.0/>)

Electronic Links: <https://newjournalurology.com/>

General Guidelines

Manuscripts can only be submitted through the journal's online manuscript submission and evaluation system, available at the link. Manuscripts submitted via any other medium will not be evaluated. Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal's guidelines. Submissions that do not conform to the journal's guidelines will be returned to the submitting author with technical correction requests. The editor reserves the right to reject manuscripts that do not comply with the above-mentioned requirements. Editors have the right to make corrections without changing the main text. The ORCID (Open Researcher and Contributor ID) number of the authors should be provided while sending the manuscript. A free registration can be done at <https://orcid.org>.

For experimental, clinical, and drug studies mandated to be approved by an ethical committee for publication in The New Journal of Urology, the authors must furnish an ethical committee approval report in line with international agreements (<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>).

In the case of experimental animal studies, adherence to animal rights guidelines ("Guide for the Care and Use of

Laboratory Animals" <https://www.ncbi.nlm.nih.gov/books/NBK54050>) is mandatory, with requisite approval from the animal ethics committee.

The "Materials and Methods" section must specify the ethical committee's approval, including the approval number, and the provision of "informed consent" by patients.

Authors are obligated to disclose conflicts of interest and financial support related to their articles.

The rules for the title page, references, figures and tables are valid for all types of articles published in this journal.

Authors are required to submit the following:

- Cover Letter
- Copyright Agreement and Acknowledgement of

Authorship Form

- Patient Consent Form
- ICMJE Disclosure of Interest
- Title Page
- Main text
- Figures
- Tables

PREPARATION OF THE MANUSCRIPT

Authors should adhere to the ICJME recommendations for "preparing a manuscript for submission to a medical journal". <https://www.icmje.org/recommendations/browse/manuscript-preparation/preparing-for-submission.html>

The articles should be written in 12-point, Times New Roman, double-spaced with at least 2.5 cm margin on all edges of each page. The main text should not include any information about the authors' names or affiliations. This information should only be included on the title page, along with their ORCID IDs, the title, abstract, and keywords.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be explained clearly in parentheses following the definition and custom abbreviations should not be used.

Statistical analysis is usually necessary to support results in original articles. Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

during the process must be specified.

Whenever a product, software, or software program is mentioned in the main text, product information (including state in the USA) must be given in parentheses, including the product name, product manufacturer, city of production, and country of the company.

All references, tables, and figures should be sequentially numbered and referred to in the main text. All pages of the manuscript should be numbered at the bottom center, except for the title page. Papers should include the necessary number of tables and figures to provide better understanding.

Authors are required to prepare manuscripts in accordance with the relevant guideline listed below:

- Randomized research studies and clinical trials: [CONSORT guidelines](#) (for protocols, please see the [SPIRIT guidance](#))
- Observational original research studies: [STROBE](#) guidelines
- Studies on diagnostic accuracy: [STARD](#) guidelines
- Systematic reviews and meta-analysis: [PRISMA](#) guidelines (for protocols, please see the [PRISMA-P guidelines](#))
- Experimental animal studies: [ARRIVE](#) guidelines and [Guide for the Care and Use of Laboratory Animals](#), 8th edition
- Nonrandomized evaluations of behavioral and public health interventions: [TREND](#) guidelines
- Case report: the [CARE case report guidelines](#)
- Genetic association studies: [STREGA](#)
- Qualitative research: [SRQR guidelines](#)

Manuscript Types

Original Articles

New Journal of Urology adopts the [ICMJE's clinical trial registration policy](#), which requires that clinical trials must be registered in a publicly accessible registry that is a primary register of the WHO International Trials Registry Platform (ICTRP) or in [ClinicalTrials.gov](#). Authors can help improve transparency and accountability in their research by recording clinical trials in a publicly accessible registry.

Original Research Articles should include subheadings below;

- Title
- Abstract
- Keywords
- Introduction
- Material and Methods
- Results
- Discussion
- Conclusions
- Figures and Tables Legend
- References

Review Articles

Review articles should provide a comprehensive overview of the current state of knowledge on a topic in clinical practice, and should include discussions and evaluations of relevant research. The subheadings of the review articles can be planned by the authors. Review articles are scientific analyses of recent developments on a specific topic as reported in the literature. No new information is described, and no opinions or personal experiences are expressed.

- Title
- Abstract (unstructured)
- Keywords (both Turkish and English)
- Main text
- Conclusion
- Figures and Tables Legend
- References

Case Reports

New, interesting and rare cases can be reported. They should be unique, describing a great diagnostic or therapeutic challenge and providing a learning point for the readers. Cases with clinical significance or implications will be given priority.

Case Reports should include subheadings below;

- Title
- Abstract (unstructured)
- Keywords (
- Introduction
- Case Presentation
- Discussion and Conclusion
- Figures and Tables Legend

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

- References

Letters to the Editor

A “Letter to the Editor” is a type of manuscript that discusses important or overlooked aspects of a previously published article. This type of manuscript may also present articles on subjects within the scope of the journal that are of interest to readers, particularly educational cases. Readers can also use the “Letter to the Editor” format to share their comments on published manuscripts. The text of a “Letter to the Editor” should be unstructured and should not include an abstract, keywords, tables, figures, images, or other media.

Letters to Editor should include subheadings below;

- Title
- Keywords
- Main text
- Figures and Table Legend
- References

Article Structure

Title page

A separate title page should be submitted with all submissions.

The title page should include:

1. The full title of the manuscript as well as a short title (running head) of ≤50 characters
2. Name(s), affiliations, highest academic degree(s), and ORCID IDs of the author(s),
3. Name, address, telephone (including the mobile phone number), and email address of the corresponding author
4. If the author(s) is a member of the journal’s Editorial Board, this should be specified in the title page
5. If the content of the paper has been presented before, and if the summary has been published, the time and place of the conference should be denoted on this page.
6. If any grants or other financial support has been given by any institutions or firms for the study, information must be provided by the authors
7. Acknowledgment of the individuals who contributed

to the preparation of the manuscript but who do not fulfill the authorship criteria should be included

Abstract

Original articles should have a structured English (Objective, Methods, Results, Conclusion). Review articles and case reports should have an unstructured abstract. Articles and abstracts should be written in accordance with the word limits specified in the table. References, tables and citations should not be used in an abstract.

Keywords

Each submission must be accompanied by a minimum of three to a maximum of six keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (<https://www.nlm.nih.gov/mesh/MBrowser.html>).

Limitations for each manuscript type;

Type of Article	Abstract word limit	Word limit	References limit	Table limit	Figure limit
Original Article	250 (Structured)	3000	30	6	5
Review Article	250 (Unstructured)	4000	50	6	5
Case Reports	250 (Unstructured)	2000	10	1	3
Letter to the Editor	No abstract	1000	5	1	1

Figures and Tables

Figures, graphics, and photographs should be submitted as separate files (in JPEG format) through the submission system. The files should not be embedded in a Word file of the main document. When there are figure subunits, the subunits should not be merged to form a single image. Each subunit should be submitted separately through the submission system.

Images should be numbered by Arabic numbers to indicate figure subunits.

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends. The minimum resolution of each submitted figure should be 300 DPI. Figures or illustrations must not permit the identification of patients and written informed consent for publication must be sought for any photograph.

Figure legends should be listed at the end of the main document. Figures should be referred to within the main text, and they should be numbered consecutively in the order in which they are mentioned.

Tables should embed in the main document. Tables should support and enhance the main text rather than repeat data presented in the main text. All tables should be numbered consecutively in the order they are used to within the main text. Tables legends should be listed at the end of the main document.

Units of Measurement

Units of length, weight and volume should be reported in metric (meter, kilogram, liter) system and in decimal multiples. Temperatures should be expressed in degrees Celsius, and blood pressures in millimeters of mercury. Both local and International Unit Systems (International System of Units, SI) should be used as measurement units. Drug concentrations should alternatively be given in either SI units or mass units written in parentheses.

Abbreviations and Symbols

Use only standard abbreviations, non-standard abbreviations can be very confusing for the reader. The use of abbreviation(s) should be avoided in the title. If there is no standard unit of measurement, provide the long version of the abbreviation in parentheses when it is first used in the text.

Supplementary Materials

Supplementary materials, including audio files, videos, datasets, and additional documents (e.g., appendices, additional figures, tables), are intended to complement the main text of the manuscript. These supplementary materials should be submitted as a separate section after the references list. Concise descriptions of each supplementary material should be included to explain their relevance to the manuscript. Page numbers are

not required for supplementary materials.

Identifying products

When mentioning a drug, product, hardware, or software program in a manuscript, it is important to provide detailed information about the product in parentheses. This should include the name of the product, the producer of the product, and the city and country of the company.

Author Contributions

During the initial submission process to The New Journal of Urology, corresponding authors must submit a signed and scanned authorship contribution form. This form is available for download through <https://dergipark.org.tr/tr/journal/1455/file/2260/download>. The purpose of this requirement is to ensure appropriate authorship rights and prevent ghost or honorary authorship.

Manuscript Retraction: Authors may withdraw their manuscript from the journal by providing a written declaration.

References

While citing publications, preference should be given to the latest, most up-to-date publications. Authors should avoid using references that are older than ten years. All the references should be written according to the Vancouver reference style. The references used in the article must be written in parenthesis, at the end of the sentences. References should be numbered in the order they appear in the text and listed in the same order in which they are cited in the text. Be consistent with your referencing style across the document.

References must contain surnames and initials of all authors, article title, name of the journal, the year and the first and last page numbers. If there are more than 6 authors, an abbreviation of "et al." should be used for the authors out of the first three.

You must add the DOI (Digital object identifier) at end of each reference.

For Examples

Article in journal: Tasci A, Tugcu V, Ozbay B, et al.

THE NEW JOURNAL OF UROLOGY

PREPARATION OF MANUSCRIPT

Stone formation in prostatic urethra after potassium-titanyl-phosphate laser ablation of the prostate for benign prostatic hyperplasia. *J Endourol.*2009;23:1879-1881. <https://doi.org/10.1089/end.2008.0596>

For Books:

Günalp İ. Modern Üroloji. Ankara: Yargıçoğlu Matbaası, 1975.

Chapters in books: Anderson JL, Muhlestein JB. Extra corporeal ureteric stenting during laparoscopic pyeloplasty. Philadelphia: W.B. Saunders, 2003; p. 288-307.

For website;

Gaudin S. How moon landing changed technology history [serial online]. 2009 [cited 2014 June 15]. Available from: <http://www.computerworlduk.com/in-depth/it-business/2387/how-moon-landing-changed-technology-history/>

For conference proceeding;

Anderson JC. Current status of chorion villus biopsy. Paper presented at: APSB 1986. Proceedings of the 4th Congress of the Australian Perinatal Society, Mothers and Babies; 1986 Sep 8-10; Queensland, Australian. Berlin: Springer; 1986. p. 182-191.

For Thesis;

Ercan S. Venöz yetmezlikli hastalarda kalf kası egzersizlerinin venöz fonksiyona ve kas gücüne etkisi. Süleyman Demirel Üniversitesi Tıp Fakültesi Spor Hekimliği Anabilim Dalı Uzmanlık Tezi. Isparta: Süleyman Demirel Üniversitesi; 2016.

Author Contribution&Copyright Transfer Form

The New Journal of Urology requires corresponding authors to submit a signed and scanned version of the authorship contribution form (available for download through <https://dergipark.org.tr/tr/journal/1455/file/2260/download>) during the initial submission process to act appropriately on authorship rights and to prevent ghost or honorary authorship.

Manuscript Retraction

For any other reason authors may withdraw their manuscript from the journal with a written declaration.

Revisions

When submitting a revised version of a paper, the author must submit a detailed "Response to the reviewers" that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer's comment, followed by the author's reply and line numbers where the changes have been made) as well as an annotated copy of the main document. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request this extension before the initial period is over.

AFTER ACCEPTANCE

Accepted manuscripts are copy-edited for grammar, punctuation, and format. A PDF proof of the accepted manuscript is sent to the corresponding author and their publication approval is requested. The journal owner and the editorial board are authorized to decide in which volume of the accepted article will be printed. Authors may publish their articles on their personal or corporate websites by linking them to the appropriate cite and library rules.

THE
NEW JOURNAL
OF UROLOGY

Volume 19, Issue 2, June, 2024

İstanbul / Türkiye

Pera Publishing Services

Address: Ataköy 3-4-11 Kısım Mah. Dr Remzi Kazancıgil Cd. O-114 N:12 D:7 Bakırköy İstanbul / Türkiye

E-Mail : info@perayayinslik.com

